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SUMMARY 
 
Technology-intensive industries such as the pharmaceutical industry have strong 
links with specialist providers of technological knowledge and receive inputs (e.g. 
advice, consultation and access to research equipment) from other actors such as 
universities. This study reports on the nature of the participating pharmaceutical 
firms’ management decision making processes in forming linkages with universities. 
 
The two research questions formulated for this study are -  
 
i. What types of linkages do pharmaceutical firms operating in South Africa form 
with South African universities?  
ii. How do South African pharmaceutical firms decide with which university/ies to 
form linkages?  
 
In order to answer the research questions, a qualitative research methodology was 
employed to collect data from elite interviews with senior executives and senior 
managers from 20 pharmaceutical firms that participated in the study. The 20 
pharmaceutical firms were represented by local and international firms operating in 
South Africa. Data was triangulated and entailed the collection of interviews from 
expert commentators drawn from universities and national government departments 
and government-owned scientific and technological knowledge-producing 
institutions.  
 
The key findings are that these firms employ search and selection processes, and 
carry out evaluation processes when they seek external specialist providers of 
technological knowledge and other inputs, which have relevance for corporate 
decision making and policy development. 
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1. CHAPTER 1: INTRODUCTION  
 
 Purpose of the research 1.1
 
The purpose of this research is to explore how the pharmaceutical firms operating in 
South Africa establish linkages with specialist providers of scientific and 
technological knowledge, such as universities.    
 
 Research questions 1.2
 
iii. What types of linkages do pharmaceutical firms operating in South Africa form 
with South African universities?  
iv. How do pharmaceutical firms operating in South Africa decide on which 
university/ies to form linkages?  
 
 Problem statement 1.3
 
There is insufficient evidence about how pharmaceutical firms operating in South 
Africa establish linkages with universities and how they choose among alternative 
sources of specialised technological knowledge.     
 
 Context of the research 1.4
 
Linkages between firms in technology-intensive industries (such energy, 
telecommunication, steel and pharmaceutical) and universities contribute to the 
economic development of countries, as they are seen as key elements of innovation 
systems and have beneficial effects to firms’ innovation processes (De Fuentes and 
Dutrénit 2012), and play an important role in fostering technology development 
(Cohen, Nelson and Walsh 2002) . For the purpose of this study, a linkage is an 
interaction between a firm and a university on research and technology development 
at the firm level, which may vary, depending on the needs of the firm. Linkages 
between firms and universities may include student training research programmes 
where students are placed in the firm to conduct a specific aspect of research 
(Meyer-Krahmer and Schmoch 1998; Bekkers and Freitas 2008), contract research 
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(Kingsley et al 1996; Monjon and Waelbroeck 2003) and university consultancy 
(Bekkers and Freitas 2008). In addition, firms have linkages with several sources of 
knowledge such as other firms, customers and suppliers. It is argued that these 
sources of technological knowledge can have a positive effect on management 
practices as well as overall firm innovation performance and productivity (Mol and 
Birkinshaw 2009). These types of linkages differ across technology industries and in 
their effectiveness to the firm innovation process and management, as well as the 
way in which knowledge is acquired by the firm from the university. According to 
Mowery and Sampat (2002), citing the  Organisation of Economic Cooperation and 
Development publication of 2002,  firms are involved in linkages with universities to 
acquire  specific knowledge in order to improve their innovation performance and 
competitive advantage over their competitors. Thus, firms choose universities for 
various reasons to form linkages, such as providers of technological knowledge 
(Gunasekara 2006), as well as to reduce risks during the technology development 
process (Arranz and Arroyabe 2008), among other reasons. The latter authors 
mentioned that one of the advantages of the establishment of linkages between 
actors (e.g. universities and firms) within an innovation system is building of trust and 
enhancement of reputation for the actors concerned or involved (Arranz and 
Arroyabe 2008).  
 
In order to understand how linkages improve technological and innovation 
performance of firms, several aspects of linkages were studied. These included the 
types, characteristics and nature of linkages (Arza and Lopez 2008; Schartinger, 
Schibany, Gassler 2001; Siyanbola et al 2012), the factors that facilitate the 
formation of linkages (Fontana, Geuna and Matt 2006; Giuliani and Arza 2009; 
Hamdan et al 2011) and the motivations and rationales for firms to form linkages with 
universities (Bayona, Garc´ıa-Marco, Huerta 2001; Brostrom 2008, 2010; Rasiah and 
Govindaraju 2009; Arza and Lopez 2011) and the benefits of linkages to firms 
(Leten, Landoni, Looy 2014; Buckley and Kafouros 2008), as well as the flow 
mechanisms of knowledge from universities to firms (Perkmann and Walsh 2009; 
Østergaard 2009; Hess and Rothaermel 2011; Zawislak and Dalmarco 2011; 
Fukugawa 2012; Erden et al 2014). The knowledge resource view literature suggests 
that firms’ internal knowledge stock accumulated from knowledge flows and the 
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choices made by the management play an important role in increasing the innovation 
performance of firms (DeCarolis and Deeds 1999; Erden et al 2014).    
 
These aspects of linkages were predominantly studied across technology-intensive 
industries using quantitative research methodologies within the context of developed 
countries, which are characterised by certain political, social, regulatory, legal and 
financial, as well as other socioeconomic attributes. There is a notable variation of 
linkages between firms and universities across technology-intensive industries. For 
example, a study in the British pharmaceutical industry indicated that the adoption of 
the research models for drug development and discovery have prompted firms to 
interact with universities in order to access new sources of innovation for novel drug 
therapies targeted for developing countries as well as to avoid high costs incurred by 
conducting basic research and the associated risks (Tralau-Stewart et al 2009).  
 
In South Africa, pharmaceutical firms have options to choose from external specialist 
providers of technological knowledge. The South African life sciences industry, which 
includes pharmaceutical firms, has been shown to have strong linkages between 
firms and universities (Al-Bader et al 2009; Kruss 2012). These firms seek out 
interactions with universities in order to have access to scientific knowledge, know-
how and research equipment to build capabilities for technology development and 
attain a competitive advantage over their competitors (Al-Bader et al 2009; Kruss 
2012). These studies report that these firms experience a number of challenges 
when collaborating with universities, including a lack of commercial knowledge, 
prolonged intellectual property negotiations and unrealistic expectations in terms of 
royalties generated from the commercial exploitation of their research. 
 
Previous work in the South African health biotechnology sector (Al-Bader et al 2009; 
Kruss 2012), which is similar to the pharmaceutical sector in terms of, for instance, 
the nature of research, technological challenges and technological knowledge 
requirements, suggests that several factors may play an influential role in firms 
forming linkages with universities. These include universities’ contributions of 
technological knowledge and other inputs to firms’ technological development and 
learning (Kruss 2012), through which firms could develop in-house capabilities 
required to manage the innovation process.  
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 Significance of the research 1.5
 
The study adopted a qualitative research design to examine decision making 
processes within selected pharmaceutical firms operating in South Africa. The 
findings of this study present an underexplored aspect of the university-industry 
linkage in developing countries, like South Africa, especially from the management 
perspective, and have policy implications on how to promote linkages between the 
pharmaceutical industry and universities in South Africa. 
 
 Organisation of the research report 1.6
 
This research project is organised in six chapters as follows:  
Chapter Two: The literature review presents key themes from academic and 
practitioner literature in line with this research. Chapter Three describes the 
exploratory nature of this study and the methodology, which includes design of the 
study, qualitative data collection, method and the analysis of data. The limitations of 
the research methodology are also outlined in this chapter. Chapter Four presents 
the findings. Chapter Five analyses the findings against findings obtained in the 
literature. Chapter Six presents conclusions and the recommendations for future 
research. 
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2. CHAPTER 2: LITERATURE REVIEW 
 
 Introduction 2.1
 
This chapter establishes an analytical framework to assess the types of linkages, 
knowledge flows and benefits that exist between pharmaceutical firms and 
universities. The chapter includes a series of empirical literature studies on this 
subject and explores implications for management decision making and innovation. 
This is based on the literature. 
 
The chapter is organised as follows: (1) the types of linkages and specialised 
knowledge flows from universities to the pharmaceutical industry; (2) linkages and 
innovation (3) how firms search for and select external specialist knowledge from 
providers; and pharmaceutical industry-university linkages and their benefits. 
 
 Types of linkages and specialised knowledge flows from universities to 2.2
industries (firms) 
 
Empirical studies on linkages between industries and universities are extensively 
documented: motivations and rationales for forming linkages with universities 
(Ramos-Vielba, Ferna´ndez-Esquinas and Espinosa-de-los-Monteros 2009; Bayona, 
Garcıa-Marco and Huerta 2000; Brostrom 2008, 2012; Ankrah, Burgess and Shaw 
2013); types and nature (Arza  and Lopez, 2011; Siyanbola et al. 2012; Fuentes and 
Dutrénit 2012); the mechanism of knowledge flows (Bekkers and Freitas 2008; 
Østergaard 2009; Purwaningrum, Evers and Yaniasih 2012; Awuor 2013) and 
benefits (Triulzi, Scholz and Pyka 2011; Fuentes and Dutrénit 2012). These studies, 
however, offer limited insights to understand how the linkages between firms and 
universities influence the management decision making processes within firms to 
transform knowledge into technologies and products that would yield financial gains 
for the business.   
 
Universities are diverse in their missions, research activities, governance and 
performance, and carry out research through public funding in the innovation system 
(OECD 2010). Their performance varies across countries and industries, and while 
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some attract human capital needed for innovation, offer education and training 
services (OECD 2010), they usually only provide research and development support 
to firms through different interactions; and can also interpret the technological needs 
of the market (OECD 2011).  Conversely, firms define the type of knowledge they 
wish to establish with universities relative to internal opportunities and knowledge 
needs (D’Este and Patel 2007), probably through various decision making 
processes. Various forms of linkages are country and industry-specific, and are 
related to the type of scientific knowledge required.  
 
It has been estimated that about 10% of the world’s products and processes in 
technological fields introduced by firms into their respective markets have been as a 
result of the contribution of specialised university knowledge inputs through linkages 
(Manfield 1998; Beise and Stahl 1999). Universities provide external specialist 
knowledge, which is scientific, and technological outputs (such as publications, 
patents and students) produced through a process of exploration in a laboratory-
based setting in which the aim is to solve a science problem (Pavitt 2003; Moroz 
2005 citing Popper 2000). Interactions between universities and industries form part 
of a system of innovation of a country, where the actors together create, diffuse and 
implement new knowledge (Innovation, Higher Education and Research for 
Development 2012).  
 
However, to date it has not been determined how interactions between industries 
and universities evolve especially from management decisions of firms. 
 
Firms involved in research and development (R&D) and technological activities 
benefit from linkages with universities on research and technology through a variety 
of specific channels (Intarakumnerd and Schiller 2009; Dutrénit, Fuentes and Torres 
2010; Kruss 2012). The development of such channels is facilitated by personal 
contact and trust between the university and firm researchers and the geographical 
proximity of a university in relation to a firm (Luizo and Burcharth 2008; Araujo et al 
2011).  Public conferences, the mobility of students, collaborative research and 
development activities, patents and meetings are also regarded as important 
mechanisms or channels through which firms are able to access university specialist 
knowledge (Dutrénit, De Fuentes and Torres 2010; De Fuentes and Dutrénit 2012). 
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Technology licenses and personnel exchanges are, however, not found to be that 
important as channels of accessing university knowledge (Bekker and Bodas-Freitas 
2008). 
 
Universities play an important role in the economic performance of firms of high 
technology-intensive industries such as biotechnology, pharmaceutical and new 
materials in countries (Veugelersa and Cassimana 2005 citing Cockburn and 
Henderson, 2000; Mowery and Sampat, 2004). However, the role of universities 
differs across industries and countries, and is influenced by several factors such as 
structure and size of an industry and the structure of publicly-funded research 
performers (Mowery and Sampat 2004). 
 
Bekker and co-authors assert that at the firm level, in the Netherlands, the more 
university knowledge is written down and published in scientific journals, it is 
searchable thereby making easier for firms to be aware of the R&D that is taking 
place in the academic environment and thus facilitating firms’ decision-making 
processes for the establishment of linkages through informal contacts and 
collaborative and contract research with potential universities (Bekker and Bodas-
Freitas 2008). Moreover, firms wishing to improve their innovation capability and 
business performance through the application of scientific published knowledge, both 
related to breakthroughs or to complex systems, need to favour scientific 
publications, informal contacts with university researchers and students as well as 
labour mobility (Bekker and Bodas-Freitas 2008). These types of knowledge transfer 
favour the combination of both scientific and technological knowledge, which is 
important to enable awareness and specification of scientific knowledge to the needs 
of firms and their markets (i.e. the adoption of that scientific knowledge by firms). 
 
Firms operating in high knowledge and technology industries such as biotechnology 
and pharmaceuticals use a wide variety of linkages to access university knowledge, 
which was dependent on the firms’ needs, industry type: knowledge type 
requirement and even the characteristics of researchers involved in producing the 
knowledge. 
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 Linkages- Knowledge Flows-- and Innovation 2.3
 
The production of external specialist knowledge by universities is often aided by 
government or public funding and policies to address socioeconomic challenges;    
and the effects of external knowledge on firms’ innovation capacity building have 
increased the attention of policy makers in developing countries to encourage 
linkages between universities and firms to bring technology change and develop a 
knowledge-based economy for economic growth (Slow 1957; Romer 1990).  
 
Many countries recognise the fundamental role of knowledge in fostering economic 
growth and development of countries (OECD 1997), mainly through industrial 
innovation (Mowery, Oxyley and Solverman 1996; Wang 2009; Lim 2004; Furman 
and MacGarvie 2007), thereby contributing to helping governments to achieve 
socioeconomic development outcomes. Knowledge is an asset, both appearing as 
both input and output in the production processes and facilitates the learning 
capabilities of firms (Lundvall 2003) and stimulates innovation and competence 
building of firms (Lundvall 2004). Thus, knowledge is closely related to the economic 
performance of firms, measured by profit (Wolff and Pett 2006; Karakas and Yildiz 
2012). Karakas and Yildiz (2012) further argue that external knowledge in relation to 
firms shapes the decision making process of multinational firms to enter new 
markets, including investment freedom, intellectual property rights and corruption.  
 
According to the concept of a system of innovation, firms form complex networks 
with universities whose activities and roles initiate, import, modify and diffuse new 
technologies into the firm (Lundvall 2004 citing Freeman 1987). Lundvall (1992) 
suggests that the concept of national innovation system refers to relationships 
between firms and universities whose primary objective is the production, diffusion, 
and use of new knowledge to contribute to new institutional make-ups enabling for 
searching for new knowledge or technologies and building learning and technological 
capabilities. 
 
Although, there are different perspectives of innovation at the firm level in practitioner 
literature, Marcelle (2011) offers another perspective of innovation which is related to 
the purpose of this study. The author describes innovation as a: 
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“process of generating, acquiring and applying knowledge for 
economically and socially beneficial purposes and takes place through 
efficient unfolding of various learning processes, rather than being 
determined by the mastery of science and technological knowledge”. 
 
While the author’s perspective on innovation contradicts a perspective on innovation 
as science-based, and produced in a laboratory environment, it offers an 
understanding of the process of how firms acquire external specialist knowledge and 
apply the knowledge with the intention of improving their own innovation and gaining 
economic benefits. Furthermore, the definition of innovation according to Marcelle 
(2011) implies that firms acquire external specialist knowledge with the intention of 
developing learning and technological capabilities (Marcelle 2004; Bell 2009), which 
are required for technological innovation (product and process innovation) and 
overall firm’s innovation performance (Atalay, Anafarta and Sarvae 2013). Firms with 
an innovation strategy based on linkages with external specialist knowledge 
providers such as universities have been shown to be more likely to survive in an 
environment where technology is changing rapidly than firms that do not have 
external linkages (Soh and Roberts 2003).  
 
Firms, including those operating in pharmaceutical industry no longer rely solely on 
internal R&D activities to achieve innovation and are therefore necessary to form 
linkages with the universities to acquire, assimilate and integrate knowledge into 
production, technology and manufacturing processes to overcome such market 
pressures and sustain competitive advantage and improve performance (Santos 
2003; Veugelers and Cassiman 2005; Jurado et al 2009). However, the challenge 
facing managers of most firms is how to search and identify the appropriate sources 
of external specialist knowledge in order to overcome the external business 
competitive environment and other pressures brought by government legislations 
and regulations.  
 
Against this background, the concept of the national innovation system redefines the 
roles of universities as specialist producers and providers of knowledge and dictates 
how knowledge gets channeled to firms in a way that it will easily be adopted 
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(Mowery and Sampat 2000). Fu and Li (2009) add another dimension into the role of 
universities from a developing country’s perspective, where they argued that 
universities should play a distinctive role in promoting the diffusion of frontier 
technology and the creation of new innovation outcomes at both the country and firm 
levels.  
 
According to Eom and Lee (2010) citing Etzkowitz and Leydesdorff (1997) there are 
two divergent views concerning the role of universities within the innovation systems, 
namely the Triple Helix school of thought and the New Economics of Science school 
of thought. The two contradictory views emphasise an important role that universities 
could play in the national systems of innovation, both in social and economic 
development of countries (Etzkowitz and Leydesdorff 1997 cited by Eom and Lee 
(2010).  
 
Thus, the Triple Helix School of thought refers to the industry-university-government 
linkages and it emphasises the social and economic value of universities in the 
national system of innovation (Eom and Lee 2010 citing Etzkowitz and Leydesdorff 
(1997). According to the Triple Helix perspective innovation takes place in a 
knowledge infrastructure where the linkages between firms, university and 
government play an important role in facilitating the conditions for innovation 
(Leydesdorff and Meyer 2013). The government creates an environment where the 
university and firms can become effective in knowledge production through policies, 
programmes and incentives (Etzkowitz and Leydesdorff (2000). The Triple Helix 
school of thought thus argues that the university needs to be directly linked to the 
firm through among other things formal meetings, joint research programmes, 
consultancy work commissioned by the industry, as well as licensing agreements of 
patents and purchasing of prototypes for industrialisation based on scientific and 
technological knowledge (Schartinger et al 2002; D’Este and Patel 2007). This then 
reiterates the third role of the university in the innovation system, which is serving for 
economic development aside from its traditional role of teaching and training 
(Etzkowitz and Leydesdorff 2000). 
 
The New Economics of Science School of thought, on the other hand, emphasises 
education as a core function of universities (Dasgupta and David 1994). This view is 
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concerned with the relationship between university and industry becoming too close, 
arguing that it may be detrimental to the scientific potentials of a nation and that a 
proper division of labour between these actors is needed (Eom and Lee 2010 citing 
Etzkowitz and Leydesdorff (1997). Criticising the inappropriateness of the two in their 
applications to developing countries, Eun and co-authors suggested a contingent or 
context-specific perspective on the linkage between firms and universities (Eun et al 
2006). Each country has its own national innovation system, and it is natural that the 
linkages between firms and universities in each country take various forms and 
assume different functions (OECD 1997). 
 
Eom and Lee (2010) investigated the role of universities within the Korean national 
system of innovation, through the analysis of the Korean Innovation Survey data, 
with a particular reference to the determinants of the linkages between firms and 
government research organisations including the universities and their effect on the 
innovation performance of firms. The authors found that firm size and research and 
development intensity do not have a significant effect on the innovation performance 
of firms. Interestingly, Eom and Lee (2010) found that university research and 
development activities turn out to be the most important determinant to the 
innovation performance of firms. According to Eom and Lee (2010), this finding is, 
however, in contrast to the findings found in literature studies performed in European 
countries. Consequently, Eom and Lee (2010) emphasise that government policies 
and legislation should play important roles in promoting linkages between firms and 
public research organisations including universities in developing countries. 
 
However, firm-university-government linkages on a firm’s innovation performance 
may influence the selection or direction of research projects of a firm (Etzkowitz and 
Leydesdorff 2000). When the analysis is limited to the innovation performance of 
firms, a positive effect of the firm-university-government linkages was observed in a 
study of Eom and Lee in 2010 on the number of patents produced from new product 
innovation due to external public research organisation and university research and 
development input into firm’s technological development process (Eom and Lee 
(2010). Although these findings were found from a study conducted in Korea by Eom 
and Lee (2010), the findings suggest that the nature of the innovation system and 
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knowledge inputs in developing countries would play an important role in firm’s 
innovation performance and industrialisation.  
 
 Innovation management and external specialist knowledge 2.4
 
Interactions between different actors such as private firms, public research 
organisations (including universities) and government departments and their policies 
are the main features of the innovation system of any country, and promote learning, 
which can take place through formal education (Lundvall 2007; Parto et al 2006). 
Government interventions through policy measures play an important role in 
promoting and shaping interactions, as well as influencing the performance of 
national innovation systems (OECD 1997). Hence, government interventions 
(through policies and incentives) account in a major way for the process which the 
public and private producers of knowledge become linked and, in doing so, influence 
the market orientation of manufacturers, and research and development at firms. 
 
Universities are seen as important agents in driving the economic and social 
agendas of countries (Innovation, Higher Education and Research for Development 
2012). This is mainly through linkages with private firms in high technology sectors 
where scientific and technological knowledge form the basis for innovation at the firm 
level. 
 
Hobday (2009) notes that innovation process models have implications for 
management decision making processes for alternative sources of specialist 
knowledge providers. Tidd and Bessant (2009) provide insights into how firms in 
developed countries manage innovation through interaction with external specialist 
knowledge providers, and how the process of innovation within firms influence 
management decision making and development. 
 
Tidd and Bessant (2009) proposed the innovation process model shown in Figure 1, 
which provides an understanding of how firms make decisions on accessing 
specialist knowledge to trigger innovation, derive value, learn and build 
competitiveness in relation to their competitors. The model is comprised of four 
dimensions: search, select, implement and capture, which show the routines that 
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firms in developed countries utilise to stimulate innovation. However, it is not clear to 
what extent firms perform these routines in order to trigger the innovation process 
and the factors involved, and whether firms go through these routines simultaneously 
or perform one routine at a time. Tidd and Bessant (2009) argue that the challenge 
for firms in managing innovation is how to strike the balance between its internal 
complementary assets and what it needs outside its boundaries to innovate and to 
do with limited resources such as people and the budget for research and 
development.  
 
 
Figure 1: Firm level innovation management process (Source: Tidd and 
Bessant 2009) 
 
Firms have different approaches to searching for, and identifying external specialist 
knowledge providers to trigger innovation (e.g. Tidd and Bessant 2009). They adopt 
a specific search approach or strategy based on the characteristics of the 
environment in which they are operating, such as organisational arrangements, 
institutional infrastructure, and the culture and legal and policy framework. These 
institutional frameworks influence how firms search for external specialist knowledge.  
Some firms can adopt different approaches of the search process simultaneously, 
thus creating more opportunities to identify potential sources of knowledge providers 
to form linkages with on knowledge development and production. However, it is not 
clear in the literature how firms choose among the different options of search for 
21 
 
external specialist knowledge and which option is more effective to enable a firm to 
identify relevant knowledge to trigger innovation.     
 
Private firms search for specialist knowledge to trigger the innovation process and 
engage in a number of approaches or strategies to search for external specialist 
knowledge [e.g. Tidd and Bessant (2009, page 263)], as illustrated in Figure 2. 
According to Tidd and Bessant (2009) firms employ search strategies to establish 
linkages with external role players in the innovation system as potential sources for 
specialist knowledge to innovate. However, the challenge facing the management of 
many firms is how to recognise and choose among a variety of search options in 
order to maximise value from external knowledge requirements in so doing with 
limited resources (Tidd and Bessant 2009).  
 
In the context of innovation management at the firm level, search is referred to as a 
process by which firms scan for innovation opportunities, as well as keep abreast of 
developments in their operating environment.  A firm employs search strategies to 
identify signals in the marketplace to trigger innovation and bring technological 
change (Tidd and Bessant 2009). Hence, search strategies have been found to 
substantially impact on the innovation performance of firms (Sofka and Grimpe 
2008). However, firms across industries differ on search depth and scope and these 
variations can lead to variations in their innovation performance, which suggests that 
some firms are able to engage in different search strategies or approaches 
simultaneously (Katila and Ahuja 2002). Firms should manage search approaches in 
a manner that would lead to the transformation of external knowledge into benefits 
(Tidd and Bessant 2009), such as new product technologies, manufacturing 
processes and services as well as market opportunities.  
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Figure 2: Search strategies by firms (Source: Tidd and Bessant 2009) 
 
Cohen and Levinthal (1990) emphasise that for firms to be effective in the search 
process, they must have internal resources that include competent staff with skills 
and knowledge to detect relevant market signals. Cohen and Levinthal (1990) refer 
these internal resources as absorptive capacity. The individuals with specialised 
knowledge and skills to conduct search processes often go out in the environment to 
locate and detect signals about the potential for change and bring back information 
to the firm for use in technological development (Pertuzé et al 2010; Hess and 
Rothaermel 2011). 
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Operating in highly intensive technology industries, which require external 
knowledge inputs for innovation and production processes, it is noted that firms differ 
in how they search for external specialist knowledge from universities. Laursen and 
Salter (2004), using a survey of firms drawn from the United Kingdom’s 
manufacturing sector, found that these firms use external search breath and external 
search depth to access external specialist knowledge to trigger internal innovation 
process. These search strategies enable firms to be open to different options to 
access external knowledge. This correlates with Laursen and Salter (2004) on the 
influential role of the search process to firms’ decisions on choosing universities and 
other research organisations.  
 
There are various factors which influence firm’s ability to choose from search 
options. These include the intensity of the internal firm research and development, 
the size of the firm and the nature of the industry (Laursen and Salter 2004).  In their 
study, Laursen and Salter (2004) suggest that firms operating in high technology-
intensive industries with small budgets for research and development have a high 
propensity to form linkages with universities on specialist knowledge.  
 
Sofka and Grimpe (2008) argue that the characteristics of the innovation system in 
which a firm operates may influence a search process to seek external knowledge. 
Each country has unique conditions characterised in terms of combinations of 
organisations and institutional arrangements and infrastructure which determine a 
firm’s ability to innovate (Sofka and Grimpe 2008). Such institutional infrastructure 
refers to public research organisations including universities involved in the 
generation and diffusing of technological knowledge, including other factors such as 
culture, legal and policy frameworks (Soka and Grimpe 2008). Firms operating in 
developed countries where innovation systems are functional and effective in terms 
of knowledge production processes, are more likely to find external knowledge 
requirements for innovation than firms operating in a developing country context. 
This implies that context matters on how firms undertake the process of search.  
 
In summary, search is an important aspect of innovation management at the level of 
the firm and has been linked to the innovation performance of firms. However, firms 
across industries vary on how they search for external specialist knowledge and this 
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variation may lead to variations in the effect of search to a firm’s innovation 
performance. Firms search for external specialist knowledge to supplement 
technological capabilities in order to gain competitive advantage in a specific 
technological niche (Stuart and Podolny 1996).  
 
 Firm-university linkages in the pharmaceutical industry and their benefits 2.5
 
The literature notes that firms that operate in industrial sectors that require external 
specialist technological knowledge such as biotechnology and pharmaceutical 
industries for innovation and enhanced business growth have linkages with 
universities to draw technological knowledge and other inputs (Laursen and Salter 
2004; Loof and Brostrom 2008). The literature suggests that universities, through 
their technological knowledge and other inputs, offer firms an opportunity to develop 
their competitive advantage in the business environment they are operating in.  
 
The industrialised sectors such as pharmaceutical industry are characterised by 
increased international competition, stiff regulatory requirements, technological 
evolution and technological complexities, and long lead timeframes for the 
commercial development of technology (Brostrom 2010 citing Gerybadze and Reger 
1999; Druker 2001). Hence, firms across the highly intensive industries are finding it 
a necessary requirement to manage internal knowledge and resources, recognising 
and selecting appropriate sources of technological knowledge providers to form 
appropriate linkages that they would benefit from to overcome external 
environmental pressures and challenges (Escribano, Fosfuri and Tribó 2009).  
 
Siyanbola et al (2012) showed that firms in the Nigerian pharmaceutical industry 
established linkages with local universities through consultancy services, staff 
exchange programmes and sponsored workshops for researchers. In contrast, 
Paranthos (2010) found that in the Brazilian pharmaceutical industry, firms and 
universities established linkages for joint collaboration, to produce knowledge and 
technologies, and mutually owned the intellectual property of their joint output. While 
both these cases occurred in similar socioeconomic contexts and innovation 
systems, the internal resources of firms, skills and hard equipment, likely contributed 
to management decisions on the nature of the linkages and the knowledge required.  
25 
 
 The South African Pharmaceutical Industry 2.6
 
According to the South African Department of Trade and Industry official report, the 
pharmaceutical industry is among the strategic industrial sectors of the South African 
economic growth and development (Department of Trade and Industry 2011). The 
industry provides employment for up to 9 600 people, most of which are 
professionals with university qualifications and skilled workers in manufacturing, 
processing and product development of drug technologies in both local and 
international firms operating in South Africa. 
  
The South African pharmaceutical industry consists of local and multinational firms 
operating in the areas of manufacturing, export, import, research and development, 
and clinical research, among others (Medicine Control Council 2011). The 
manufacturing industry focuses on generic drugs (Mahomedy 2010), which are 
medicines that have been taken off patents and are readily available for 
manufacturing (South African Healthcare Report 2009; Mahomedy 2010).  In 2011, 
the MCC issued licenses to 438 pharmaceutical companies to operate in their 
respective areas of business, including firms operating in the wholesale industry 
(Medicine Control Council 2011). The MCC also issues a license to pharmaceutical 
firms performing clinical research in South Africa. Firms involved in clinical research 
often involve universities in their clinical research activities, such as patient 
recruitment and clinical protocol design (Academy of Science of South Africa 2009).  
 
Key local pharmaceutical players include Adcock Ingram Ltd and Aspen 
Pharmacare, the largest generics manufacturer in the southern hemisphere. 
International pharmas— GSK (UK), Sanofi-Aventis (France), BMS (US), and 
Johnson & Johnson (US) have operations in the country (South African Healthcare 
Report 2009; Mahomedy 2010). US companies operating in South Africa lead the 
international firms, supplying over one fifth of the market, followed by German, 
British and Swiss firms (Business Monitor International 2009; Mahomedy 2010). 
 
South African companies feature prominently in the pharmaceutical market share of 
most developed countries including the United States of America (USA), 
Switzerland, France, Germany, Great Britain, Denmark, India, Japan and Australia 
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(Business Monitor International 2009; Mahomedy 2010). Conversely, pharmaceutical 
companies from these countries are operating in South Africa. Thirty-nine percent of 
pharmaceutical firms in South Africa are local (Business Monitor International 2009); 
21% from the USA, 11% from Switzerland, 9%  France, 7% Germany, 6% Great 
Britain, 2% Denmark and India (each), and Japan and Australia 1% each. 
 
It is reported that the size of the market for the pharmaceutical industry in South 
Africa has reduced, both in size and total income (Business Monitor International 
2012). The reduction has subsequently affected the industry’s ability to build the 
technological capability needed to delivery desirable health care in South Africa to 
patients especially those infected by HIV and AIDS and tuberculosis.  
 
According to Malodney and Myburgh (2007),  pharmaceutical firms are losing 
capabilities, especially in the area of innovation process value chain, such as in 
research and development and manufacturing activities due to limited human 
resources capacity and skills (Maloney and Myburgh 2007). According to the 2006 
Global Competitive Report on the performance of developing countries in innovation 
within the pharmaceutical sector, South Africa scored poorly compared to Singapore, 
India, China and Brazil. Maloney and Myburgh (2007) suggest that innovative 
capacity can be improved within pharmaceutical firms operating in South Africa if the 
government offers fiscal and policy support for R&D and manufacturing capabilities. 
Moreover, Myburgh (2007) asserts that government support can be in the form of tax 
incentives, grants and the promotion of linkages with universities and science 
councils. Furthermore, these forms of government support for the private sector 
pharmaceutical firms could boost innovative capacity and capability and promote the 
innovation system within the sector, as a mechanism for encouraging specialists to 
remain in the country. 
 
The leading pharmaceutical firms operating in South Africa in terms of 
manufacturing, research and development, and clinical research activities as well as 
profit revenue are indicated in Box 1:   
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Box 1: The leading pharmaceutical firms operating in South Africa 
 Adcock Ingram Healthcare (Pty) Ltd 
 Aspen Pharmacare Holdings Ltd 
 Astrazeneca Pharmaceuticals (Pty) Ltd 
 Cipla Medpro South Africa Ltd 
 Eli Lilly (SA) (Pty) Ltd 
 Glaxosmithkline South Africa (Pty) Ltd 
 GM Pharmaceuticals (Pty) Ltd 
 Gulf Drug Company (Pty) Ltd 
 Ingelheim Pharmaceuticals (Pty) Ltd 
 Johnson & Johnson (Pty) Ltd 
 Merck Pharmaceutical Manufacturing (Pty) Ltd 
 MSD (Pty) Ltd 
 Novartis South Africa (Pty) Ltd 
 Pfizer Laboratories (Pty) Ltd t/a Pfizer South Africa 
 Pac-Con Pharmaceuticals (Pty) Ltd 
 Ranbaxy (SA) (Pty) Ltd 
 Roche Products (Pty) Ltd 
 Sandoz South Africa (Pty) Ltd 
 Sanofi-Aventis South Africa (Pty) Ltd 
Source: Mahomedy (2011) 
 
Research and development activities  
 
Research and development are the backbone of the South African pharmaceutical 
industry and feeds into the innovation process for drug development and discovery.  
However, at any stage, the innovation process may have to be abandoned if it is not 
showing desired results both in terms of effectiveness and safety of drug 
technologies. Although the research and development expenditure by firms has 
shown a significant increase, research and development productivity has come 
down. All these factors have led to added pressure on the profit margin of the 
leading pharmaceutical firms and thus there is a pressing need to cut down the 
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costs. This suggests that pharmaceutical firms would opt to form linkages with 
universities as a way in which to lower the cost of research and development. 
 
The South African research and development within the pharmaceutical industry has 
largely been restricted to product development issues such as the formulation and 
stability of drug technologies, although there are new drug discovery projects in a 
number of public-private partnerships and in public research institutions including 
universities (National Association of the Pharmaceutical Manufacturers 2011). 
According to Business Monitor International (2009), the South African 
pharmaceutical industry spent 2 billion Rand (US$ 0.2 billion) in 2009 in 
pharmaceutical R&D primarily towards clinical research centered on clinical trials of 
HIV/AIDS treatments due to the large HIV-positive population.  
 
Clinical research activities 
 
The South African clinical trial research sector is the best established as compared 
to the export and import markets of pharmaceuticals (Business Monitor International 
2009 citing Academy of Science of South Africa 2009). This is mainly as a result of 
the high burden of infectious diseases, such as HIV and AIDS (Centre for the AIDS 
Programme of Research in South Africa 2007), followed by TB and non-infectious 
diseases, such as heart disease, diabetes respiratory diseases and cancer.  In 
addition to population diversity in South Africa, a majority of multinational 
pharmaceutical firms find South Africa as the best choice to conduct clinical 
research. 
 
According to a  2009 report by the Academy of Science of South Africa, clinical 
research refers to research primarily conducted with human participants (and on 
material derived from them, such as tissues, specimens and cognitive phenomena) 
during which clinical investigators examine the mechanisms, causation, detection, 
progression and reversal of human diseases (Academy of Science of South Africa 
2009). Thus, clinical research contributes to health care at all levels by identifying the 
causes of problems, facilitating diagnosis, improving the efficiency and effectiveness 
of care, and promoting good policy-making.  
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Clinical research is regulated by the MCC in areas such as research ethics, 
academic and private research ethics committees in South Africa. The application for 
approvals to the regulatory authority and ethics committee is a parallel process. All 
clinical research conducted in South Africa must be registered in the South African 
National Clinical Trials register. Each clinical trial on the register is issued with a 
unique number. 
 
To provide high quality clinical research and to protect clinical trials and human 
participants, pharmaceutical firms go to great lengths to identify suitable researchers 
at universities and research sites that meet both ethical and regulatory criteria. 
Pharmaceutical firms conduct intensive feasibility assessments prior to the selection 
of universities to collaborate on clinical research. According to the South African 
Clinical Research Association, there are seven good reasons to conduct clinical 
research in South Africa, namely, good infrastructure; high standard of medical care 
and practice; experienced researchers; robust regulatory system; stringent ethics 
oversight for research participant protection; international acceptability of data; 
diverse population and disease profiles (Academy of Science of South Africa 2009). 
 
Clinical research is important because it can improve health outcomes by 
establishing the effects of health care interventions, and because it promotes and 
facilitates best-possible health care practices. It is, therefore, a crucial element in 
building capacity, building appropriate human resources and providing training and 
education to deliver effective clinical services. Revitalising the clinical research 
environment is thus important for the interest of South Africa to stimulate new drug 
development technologies to reduce the burden of diseases. Delivering on efficient 
clinical research requires effective and supportive management decision-making at 
all levels with pharmaceutical firms. 
 
The Academy of Science of South Africa (2009) report mentions the two critical 
perspectives in clinical research. The first perspective is about the application of 
clinical research to epidemiological methods in the search for valid answers to 
questions regarding diagnosis, prevention, therapy, prognosis, etiology and other 
issues relevant to patient care. The second perspective, which is encountered in the 
pharmaceutical industry, is part of the research and development (R&D), drug 
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technology development and innovation process aimed at establishing the risks and 
benefits associated with new pharmaceutical products.  
 
South Africa has a long history of conducting clinical research and a reputation for 
good study conduct, and as an ideal clinical trial destination. It is ranked 20 out of 40 
leading countries according to the number of sites/population such as China, India, 
US and United Kingdom (Academy of Science of South Africa 2009). Although South 
Africa has been regarded as the best place to conduct clinical research investigation 
(due to diverse demographics and high burden of diseases) by the multinational 
pharmaceutical firms around the world, it is emphasised that the country displays its 
competitiveness through high quality clinical research performance (Academy of 
Science of South Africa (2009).  
 
 Linkages between firms and universities in the South African 2.7
Pharmaceutical industry 
 
 The pharmaceutical firms operating in South Africa enter into linkages with public 
research organisations including universities mainly to overcome technological 
competition and fulfil a demand for local supply of technological drugs, among other 
reasons (Kruss, Adeoti and Nabudere 2009). The major pharmaceutical firms are 
currently attempting to use their cost advantage to access knowledge from public 
research organisations including universities. Strong compliance with global 
standards and elaborate in-house research and development activities, both of which 
are encouraged by public policies, make pharmaceuticals a preferred partner for 
contract research with public research organisations. Along with public research 
institutions, they are creating a high profile for outsourcing research and 
development activities and manufacturing for both the local and international market.  
 
Firms’ motivation to form linkages with universities is to have access to scientific 
knowledge, know-how, and research equipment in order to build their capabilities for 
technology development and attain a competitive advantage relative to their 
competitors (Al-Bader et al 2009). However, they experienced a number of 
challenges collaborating with universities, which included a lack of commercial 
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knowledge, prolonged intellectual property negotiations and unrealistic expectations 
in terms of royalties generated from the commercial exploitation of their research. 
 
Case studies that Kruss, Adeoti and Nabudere (2009) focused on, revealed a 
mismatch between university and local firm capabilities. The first case study example 
was located at the University of Western Cape with a strong biotechnology expertise 
and capability. Cooperation between biotechnology firms and this university primarily 
takes the form of university-based spinoff micro-enterprises offering bioinformatics 
consultancy services to foreign customers and clients. The main beneficiaries are 
the individual academics who are permitted to increase their salaries, but there are 
few academic or financial benefits to the university.  
 
The second case study was based at the University of Cape Town with a strong 
scientific research capability and reputation locally and globally (Kruss, Adeoti and 
Nabudere 2009). The case frontier scientific research, new to the world, but directly 
oriented to the human development health needs of South Africa and sub-Saharan 
Africa. The research has potentially significant social value, whether in relation to 
HIV/AIDS vaccines, tuberculosis or hypertension. The university benefited in terms 
of publications, students and evidence of its contribution to address national health 
priorities, and drug, vaccine and device development is proceeding at various stages 
through trials to the market. All of the firms involved are foreign, whether interacting 
in the role of sponsor, customer, supplier of services, or partner in a start-up 
company. Key gaps in the local supply chain drive co-operation with foreign firms: 
local capacity for producing vaccines, even for trial quantities, has been eroded; few 
internationally compliant and certified laboratory facilities for monitoring trials exist; 
the lack of local venture capital means that investment partners are sought abroad; 
and the small size of local demand drives the search for foreign partners to assist 
with access to global markets.  
 
Yet it is significant that universities do have levels of scientific production that are 
sufficiently strong to attract global firms as business or research partners. From the 
two case studies, it can be deduced that the challenges of developing conditions and 
capacity for science-led firm selection within the health biotechnology (including 
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pharmaceutical firms), and for creating emergent new products innovations, need to 
mature further, given the fragile links within the national system of innovation. 
 
The South African pharmaceutical industry, especially in the area of health, is not 
able to take advantage of the latent opportunity inherent in existing scientific 
research and knowledge generation capability, but it is unlikely that university-led 
commercial ventures can drive the process without a core local productive sector 
with key capabilities along the innovation value chain. 
 
According to the article in the July/August Magazine on Science and Technology of 
2014 published by the South African National Department of Science and 
Technology, the multinational pharmaceutical firm - Pfizer and North-West University 
have established a linkage on pre-clinical research – a field regarded as important in 
the development of new drug technologies (Viljoen 2014). Although, it is not clear 
how a linkage was established, a Memorandum of Understanding between Pfizer 
and North-West University was signed to initiate the process for the establishment of 
linkages on potential scientific research projects in the area of pre-clinical research, 
as well as on Pfizer’s genetically modified animal models for the evaluation of the 
safety and efficacy profiles of drug technologies that would be developed by North-
West University (Viljoen 2014). The article reports that the linkage between Pfizer 
and North-West University would focus on developing drug technologies to address 
infectious and chronic diseases that are relevant to South Africa, as well as in the 
rest of African continent. 
 
The North-West University is equipped with trained researchers in pre-clinical 
research, as well as the pre-clinical research infrastructure such as facilities that 
serve as national study and supply infrastructure for qualitative and quantitative pre-
clinical studies for researchers across South Africa. The pre-clinical research 
infrastructure was established through funding from the South African National 
Department of Science and Technology. The pre-clinical research infrastructure of 
the North-West University uses safety models, in combination with bioanalytical 
expertise to speed up research and development, and drug technology development 
processes. It may be deduced that Pfizer has selected North-West University on the 
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basis of availability of skilled and experienced researchers coupled to the 
infrastructure in pre-clinical research. 
 
According to the article of Viljoen 2014 (2014) published in the Department of 
Science and Technology magazine, the research that is able to advance science and 
innovation and patient health is one of the key research and innovation strategies of 
Pfizer, to produce scientific technologies for patients in South Africa as well as the in 
the rest of the African continent (Viljoen 2014). Furthermore, the article mentions that 
Pfizer believes that its linakges with the North-West University is a key to expediting 
the translation of science into technologies for patients’ health. This will be also be 
enabled by the creativity, flexibility and openness, as well as talent and resources to 
innovate where it matters to improve patient health. The article further mentions that 
the innovation strategy of Pfizer thus entails interacting and collaborating with 
patients foundations, patients, government, funders, health care professionals, 
academia and other leading firms in biopharmaceutical and biotechnology to 
ultimately produce drug technologies that are relevant to improving the health of 
patients.  
 
The Department of Science and Technology has classified the linkage between the 
University of North West and Pfizer as among the initiatives of the South African 
government to contribute to the growth and development of the South African 
Bioeconomy sector of South Africa (Viljoen 2014). The Bioeconomy Strategy of 
South Africa, which was launched during 2014, seeks to create an environment that 
encourages the establishment of linkages between pharmaceutical firms and 
universities in South Africa to develop and produce drug technologies that can be 
introduced on the market to improve patient health (Bioeconomy Strategy 2014). 
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3. CHAPTER 3: RESEARCH STRATEGY AND METHODOLOGY 
 
This chapter presents the research methodology and strategy used in this study in 
order to answer the two research questions formulated for the study. The chapter 
introduces triangulation to validate the perspectives of the pharmaceutical firms that 
participated in this study.  
 
 Qualitative research 3.1
 
This study employed qualitative research methodology instead of quantitative 
research methodology due to the small sample size of the 20 pharmaceutical firms 
operating South Africa that participated in the study. According to Van Maanen 
(1979), who is cited by Carcary (2009):  
 
“A qualitative research includes an array of interpretative techniques which 
seek to describe, decode, translate, and otherwise come to terms with the 
meaning, not the frequency, of certain more or less naturally occurring 
phenomena in the social world” 
 
In qualitative research, the researcher seeks to achieve an in-depth understanding of 
the different meanings that people hold and place on their perspectives (Cooper and 
Schindler 2011). Hence, this study used qualitative research to explore the 
perspectives of these firms and their linkages with universities.   
 
 A qualitative research process 3.2
 
3.2.1 Development of the interview questions and interview protocol 
 
The broad academic and practitioner literature used in this study facilitated the 
development of a framework from which open-ended and closed interview questions 
were formulated. Open-ended questions enabled the researcher to understand the 
innovation profile of the pharmaceutical firms as well as of the respondents. They 
further allowed the respondents to express their views without time limitations placed 
on them other than depicting abstract generalisations. The advantage of open-ended 
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questions is the full richness and complexity of the views provided by the 
respondents. The disadvantage is the unlimited time that the respondents can have 
to express their views (Denscombe 2003), which may cause them to become 
unwilling to participate in the research (Denscombe 2003). This was experienced in 
one case in this study when a respondent from a pharmaceutical firm terminated the 
interview due to other commitments, after spending a lot of time expressing himself 
in response to a question. 
 
The development of closed and open-ended questions led to the design of the 
interview protocol which comprised of the different sections. The interview protocol 
directed to the pharmaceutical firms participated the study is indicated in Appendix 
A.  
 
The interview protocol consisted of Part 1 and Part 2 questions. Part 1 questions 
elicited a general overview of the firm as well as of the individual respondents. Part 2 
questions drew out a general understanding of the internal activities of the firm from 
the innovation perspective. It was divided into four sections: 
 
First section: “Searching for universities for collaboration and innovation.” This 
section explored how the firms searched for technological knowledge and other 
inputs from the universities; and how they operationalised the search function. 
 
Second section: “Selection criteria for choosing among knowledge providers”. 
This section explored the factors that influenced the firms’ selection processes of 
choosing universities. The section further explored the characteristics of the 
universities that captured firms’ interest in forming linkages.  
 
Third section: “Types of knowledge and learning from the university 
knowledge”. This section explored the types of university knowledge that the firms 
sought from the universities and how/what they learned from those knowledge 
inputs. 
 
Fourth section: “Value”. This section explored how the firms derive value from 
linkages with the universities; and how they capture that value. 
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 Research strategy 3.3
 
3.3.1 Sampling frame 
 
Denscomber (2007) defines a sampling frame as an objective list of the population 
from which the researcher can make a selection of the participants to be involved in 
the study. A sampling frame allows the researcher to choose elements relevant for 
the study; and to determine possible answers to the central questions formulated for 
research. The sampling frame for this study is presented in Appendix B. It consists of 
the pharmaceutical firms operating in South Africa. The sample frame was identified 
from the website of the South Africa’s Medicine Control Council (Medicine Control 
Council 2011). The Medicine Control Council (MCC) is the government institution 
responsible for regulating clinical trials, to test new drug candidates, and to issue 
licenses to pharmaceutical firms wishing to operate in South Africa in various 
business activities, such as manufacturing, export and import of drugs and 
medicines. The sample frame study excluded the pharmaceutical firms involved in 
the retail and distribution of drugs and medicines because they are unlikely to form 
linkages with universities.  
 
Table 1 shows the number of pharmaceutical firms found in each South African 
province. As of 2011, there are 263 pharmaceutical firms licensed to operate in 
South Africa (Medicine Control Council 2011). These pharmaceutical firms represent 
the sample frame for the study at the time of the research was undertaken.  
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Table 1: The sample frame of the pharmaceutical firms for this study 
South African Provinces Number of pharmaceutical companies 
1. Gauteng 196 
2. Western Cape 24 
3: KwaZulu Natal 20 
4. Eastern Cape 13 
5. North West 5 
6. Free State 3 
7. Mpumalanga 1 
8. Northern Cape 1 
TOTAL 263 
Sub-population represents a Province in South Africa. No pharmaceutical firms are present in  
the Northern Province. 
 
 
3.3.2 Selecting the pharmaceutical firms and identifying the respondents  
 
Pharmaceutical firms were selected following a review of their websites to ascertain 
whether their involvement in research and development activities, clinical research 
and technology development. Firms that showed involvement were identified for 
inclusion in this study and assumed to have linkages with universities. 
 
The identified pharmaceutical firms were contacted via email and or telephone 
requesting them to participate in this study. Eleven international and nine local 
pharmaceuticals operating in South Africa emerged from the sample frame and 
participated in the study (Table 2). These firms represent the sample size and 
interviews for this study. The pharmaceutical firms are located in the Gauteng, 
Western Cape and KwaZulu Natal provinces participated in the study. 
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Table 2: The pharmaceutical firms operating in South Africa that participated in the study 
Firm Firm core activity Location International Local  
(South Africa) 
1 Manufacturing; Clinical research; & Research and 
Development 
Gauteng  X 
2 Clinical research Gauteng  X 
3 Manufacturing; and Packaging Western Cape  X 
4 Research and Development Gauteng  X 
5 Manufacturing; & Export Gauteng  X 
6 Import; Clinical research; and Quality control Gauteng X  
7 Manufacturing KwaZulu Natal  X 
8 Clinical research Gauteng X  
9 Manufacturing; and Distribution Gauteng X  
10 Manufacturing; Export; Import; Marketing; and Distribution Gauteng X  
11 (a) Clinical research Gauteng X  
12 (b) Clinical research Gauteng X  
13 Clinical research; Import and Quality control Gauteng X  
14 Manufacturing; Export; and Research and Development Gauteng X  
15 Manufacturing Gauteng  X 
16 Manufacturing; Research and Development Gauteng X  
17 Manufacturing; Clinical research Gauteng X  
18 Manufacturing; Export; Import; Packaging Western Cape X  
19 Manufacturing; Import; and Clinical research Western Cape  X 
20 Import; Research and Development; and Distribution Gauteng  X 
Number of the international and local pharmaceutical firms participated 11 9 
TOTAL NUMBER OF THE PHARMACEUTICAL FIRM PARTICIPATED 20 
NOTE: Firm 11 (a) and 12 (b) represent the same firm; Location denotes a Province of South Africa
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3.3.3 Convenient sampling of the respondents 
 
 
Initially, the researcher had planned to conduct proportional sampling of the 
respondents from the pharmaceutical firms, holding positions such as Managers of 
Research and Development, Commercialisation, Intellectual Property, Strategic 
Collaboration, Senior Technology Acquisition and general Project Managers. The 
assumption was that these respondents were involved in projects with linkages with 
the universities and thus would provide insights.  
 
Additionally, the researcher encountered challenges to increasing the number of 
respondents and pharmaceutical firms that participated in the study; hence a 
convenience sampling technique was adopted. Denscomber (2007) defines 
convenience sampling as a selection of research participants based on the 
convenience of the researcher from which the researcher has easy access to 
conduct qualitative research.  
 
Subsequently, convenience sampling resulted in the nature of the respondents for 
the study, with the exception of two respondents who held positions as Managers for 
Research and Development and Technology Transfer Pharmacist (Table 2). The 
respondents represented senior managers and executives. It is noted that two 
respondents from the same pharmaceutical firm participated in the study and hence 
there were 20 respondents in total (Table 3).  
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Table 3: The respondents from the pharmaceutical firms 
Firms Respondents Position in the company 
1 1 Operations 
2 2 Managing Director 
3 3 Research and Development Manager 
4 4 CEO 
5 5 Technology Development Manager 
6 6 Medical Director 
7 7 Business development; Marketing and Sales, Drug 
Information, Procurement of Active Pharmaceutical 
Ingredients 
8 8 International Clinical Research Operations 
9 9 Senior Executive, Strategic Trade Development 
10 10 Managing Director 
11 (a) 11 Operation Lead 
12 (b) 12 Head of Clinical Research 
13 13 Clinical Research Manager 
14 14 Technology Transfer Pharmacist 
15 15 CEO 
16 16 Business Unit Manager Pharmaceuticals 
17 17 Compliance Oversight – Translational Lead – Africa 
18 18 CEO  
19 19 General Manager 
20 20 CEO 
NOTE: 11 (a) and 12 (b) represent one pharmaceutical company. Two individuals 
holding positions of Operational Lead and Head of Clinical Research participated in 
the study, respectively 
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3.3.4 Conducting the interviews 
 
The researcher explained the purpose of the interview to each respondent. 
Interviews were conducted by telephone and face-to-face with the respondents who 
held managerial and executive positions at their firms. Seventeen telephonic and 
four face-to-face interviews were conducted. The primary reason for including a 
telephonic interview was because of the difficulty of securing an appointment on the 
calendars of most respondents who were otherwise willing to participate.  
 
Face-to-face interviews were conducted with respondents who were willing to meet 
with the researcher in person. Unfortunately, respondents did not allow their 
interview to be tape recorded. This was probably due the competitive nature of the 
South African pharmaceutical industry as the respondents did not want to be quoted 
or have their identity revealed.   
 
A systematic approach to interviewing was adopted to keep the interview sessions 
on schedule, and focus the respondent on answering the questions. However, in 
some interviews the respondents favoured a more flexible approach. For example, at 
the request of some respondents, the interview protocol was sent to them a week in 
advance so that they could familiarise themselves with the questions, and prepare 
their responses. This probably created bias since the respondents had time to 
prepare for the responses prior the research interview. The researcher may assume 
that the bias had resulted in the type of findings obtained. 
 
A weakness of sending an interview protocol in advance to the respondents was the 
lack of questions directed to solutions that the respondents could describe. While the 
respondents expressed several solutions to issues, the lack of specific solution to 
questions reduced the richness of the findings. In addition, when using semi-
structured interviews, a bias may be introduced by the interviewer or the interviewee. 
The comments and questions may shape the responses in a way that imposes the 
interviewer’s opinion. Some interviewees asked for the opinion of the researcher but 
the researcher clarified terms or the meaning(s) of a question but refrained from 
giving an opinion. 
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The structured interview approach was adopted to gain control of the interview 
process and used as a means to identify the factors emerging from linkages with 
universities. This technique subsequently enabled the researcher to focus the 
respondents on the relevant issues. 
 
Depending on the respondents’ innovation and business experience background and 
interest, some questions were explored in greater detail whereas other questions 
were not dealt with at all. The advantage of the semi-structured approach to the 
interview is that it enables the interviewer to probe and clarify answers in order to 
understand the reasons for decisions, attitudes and opinions (Denscomber 2007). It 
provided the researcher the opportunity to pursue issues that may surface instead of 
restricting the matter of the researcher’s preconceived ideas.  The interviews took on 
average 45 - 60 minutes. 
 
3.3.5 Triangulation 
 
Due to the limited sample size of the pharmaceutical firms, multiple sources of data 
were collected for triangulation. This strategy of data collection reduced the risk that 
the research conclusions reflected only the systematic biases or limitations of the 
interviews. Thus, triangulation allows the researcher to seek convergence and 
corroboration of research findings from methods designed for the study seeking to 
understand the same phenomenon (Muskat et al 2012).  
 
Interviews were conducted with expert commentators drawn from universities (five 
respondents) and government departments and government knowledge generation 
institutions (five respondents). There were therefore 10 respondents interviewed in 
this study. Interviewing both groups of expert commentators provided a wider range 
of information about the perceptions of the pharmaceutical firm linkages with the 
universities.  Each interview took a maximum of 30-45 minutes. The interview 
protocol directed at expert commentators is indicated at Appendix C. 
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3.3.6 Qualitative data analysis 
 
The raw data from the interview responses were collated, summarised and 
organised in an Excel spreadsheet. This helped the researcher to create meaning, 
identify possible common ideas that emerged from all the respondents, and to begin 
the analysis.  
 
The data were coded in an Excel spreadsheet using the selective coding as 
suggested by Cooper and Schindler (2011). This process involved the selection of 
various categories and sub-categories, which were captured on the Excel 
spreadsheet and compiled into units of analysis. In the analysis of the data, open 
coding was used. The aim of open coding is to develop categories in terms of their 
properties and dimensions (Denscombe 2003). The coding assisted the researcher 
to identify patterns in the responses and new insights. 
 
Notes were open-coded by assigning conceptual labels to each identified unit of 
data. Open coding enables the investigators to break through subjectivity because 
fracturing the data forces preconceived notions and ideas to be examined against 
the data itself (Cooper and Schindler 2011). During the coding process comparison 
and contrasting took place. This ongoing process of data units with one another and 
with the named codes and categories, observing what is similar and different, 
allowed for the clarification of what happened to be uniform and stable in the data 
(Cooper and Schindler 2011). 
  
A type of axial coding was also used to determine the relationships between data. 
This was followed then by selective coding to determine relationships and themes 
between categories of data that had emerged from open coding. The relationships 
and themes between categories of data were identified and rearranged in a 
hierarchical order with the emergence of subcategories. Creation of subcategories 
was used particularly when a category was over populated with data. In this way, 
phenomena could be explored and explained by identifying what was happening and 
why, and what the outcomes are of the action that had been taken (Cooper and 
Schindler 2011). The theoretical categories were compared to clarify the 
relationships and themes between them. As emphasised by Denscombe (2003), this 
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process was repeated in order to refine the explanation to which the researcher in 
the present study was working.  
 
Due to the small sample size of the pharmaceutical firms that were interviewed, it 
was not envisaged that saturation of the data could have been reached in each of 
the categories. In other words, a point during the data collection when it ceases to 
reveal new data that are relevant to a category, where categories have become well 
developed and understood (Cooper and Schindler 2011). When all the insights that 
emerged from the data were identified and coded, frequency tables and graphs were 
used to present the findings. The data from triangulation was also analysed in the 
same way. 
 
 Limitation of the study 3.4
 
 Sampling limitations are present as the research makes use of convenience 
sampling. Convenience sampling does not attempt to sample in such a way 
as to be representative of the population (Patel, Tang and Elliot 2005). A 
generalisation of the population can only be made if the sample is 
representative of the population (Patel et al 2005). The research focused only 
on the pharmaceutical firms that have R&D programmes in-house and are 
involved in clinical research activities with universities. Additionally, telephonic 
interviews were only considered for the firms that became a challenge to 
secure a face-to-face interview but were willing to participate. Face-to-face 
interviews were conducted with the pharmaceutical firms that could meet the 
researcher in person. A fairly low number of firms were included in the 
sample. The results are therefore reported tentatively, to be treated as 
indicative and not conclusive. 
 Extensive firm knowledge of respondents may be limited due to recent 
employment or a narrow scope of their function. Data obtained from these 
respondents may not represent the firm perspective. 
 The research considered the decision-making approaches such as the search 
and the selection functions in so far as they are considered by firms operating 
in high-intensive technologies industries like the pharmaceutical industry. 
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3.4.1 Summary: Chapter 3 
 
The present research employed a qualitative research methodology instead of a 
quantitative research to answer the two central questions developed for the study. 
The use of qualitative research in the study was due to the small sample from the 
sample frame of the pharmaceutical firms operating in South Africa. 
 
Triangulation was included in the study by interviewing expert commentators drawn 
from the South African universities as well as from government departments and 
government knowledge-generating institutions. The aim of including triangulation 
was to validate the views and perspectives of the pharmaceutical firms obtained from 
earlier interviews and get additional insights. In total, 10 expert commentators were 
interviewed. 
 
Twenty pharmaceutical firms participated in the study to investigate their linkages 
with the universities. The research findings from the pharmaceutical firms, 
universities, government departments and government knowledge-generating 
institutions were obtained, and later organised, coded and analysed. The detailed 
presentation of the research findings is in Chapter 4.  
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4. CHAPTER 4: RESULTS 
 
 Introduction 4.1
 
The present research concerns linkages between the pharmaceutical firms operating 
in South Africa interviewed and universities in South Africa, with particular reference 
to innovation management and decision making processes by the firms. The chapter 
presents the research findings in detail, obtained from elite interviews with the 
pharmaceutical firms and the findings obtained from interviews with expert 
commentators drawn from South African universities and government departments 
and government knowledge generation institutions during the triangulation stage of 
this research. This qualitative data has been represented in a simple quantitative 
format in this chapter in order to provide a sense of the relative preference for certain 
instruments or practices as articulated by the respondents. A more critical and 
reflexive explanation of these findings and their relationship to the reviewed literature 
is later given in Chapter 5. 
 
 The profile of the pharmaceutical firms 4.2
 
The pharmaceutical firms interviewed comprised of both international firms (also 
referred to as multinationals) and local (South African) firms operating in South 
Africa. Figure 3 depicts the percentage of the pharmaceutical firms in different 
provinces of South Africa. The pharmaceutical firms that participated in the study are 
located in Gauteng, Western Cape and KwaZulu Natal.  
 
The majority of pharmaceutical firms were from the Gauteng province (80%), 15% 
from the Western Cape and 5% from KwaZulu Natal. There were no pharmaceutical 
firms from the other provinces that participated in this study.  
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Figure 3: The percentage of the pharmaceutical firms participated in this study 
according to the provinces of South Africa 
 
In the study, 55% of the local and 45% of the international pharmaceutical firms 
operating in South Africa participated (Figure 4). The firms were interviewed to 
explore the perspectives of senior and executive managers on the formation of 
linkages with South African universities and the decision making process.   
 
 
Figure 4: The percentage of the international and South African 
pharmaceutical firms operating in South Africa participated in the study  
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In total  28% of the firms are involved in manufacturing generic drugs, 21% are 
involved in clinical research activities, 12% in research and development (R&D) and 
the importation of drugs manufactured elsewhere in the world and 9% in export 
activities of generic drugs (Figure 5). The firms were involved in more than one 
business and innovation activity. The professional profile of the respondents is 
provided in Table 3 in Chapter 3 of this report.  
 
 
Figure 5: The percentages of the pharmaceutical firms involved in different 
business activities in South Africa  
 
 
 The innovation activities of the pharmaceutical firms 4.3
 
This section provides a background of the innovation activities of the pharmaceutical 
firms that participated in the study, with particular reference to the collaboration 
activities of the pharmaceutical firms participated, the nature of the firm collaboration 
with the universities and in-house firm R&D activities. These innovation activities are 
presented here because they are closely related to the research questions 
formulated for this study. A detailed account of the innovation activities of the 
pharmaceutical firms is presented in Appendix D.  
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4.3.1 Collaboration between the pharmaceutical firms and universities 
 
Ninety-five percent of firms indicated that they have had collaborations with 
universities. This is illustrated in Figure 6. 
 
 
Figure 6: The percentage of the pharmaceutical firms in terms of collaboration 
with universities  
 
4.3.2 Nature of knowledge collaboration  
 
The nature of collaborations of the pharmaceutical firms with universities is illustrated 
in Figure 7.   
 
Figure 7: Nature of the knowledge collaboration between the pharmaceutical 
firms and universities, (n = 35) 
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4.3.3 Firm-university collaboration for technology development and innovation 
 
The percentage of pharmaceutical firms’ collaboration with universities for 
technological development and innovation is indicated in the graph in Figure 8. Sixty 
percent viewed university collaboration as important for the development of 
technologies and innovation. All agreed that they have derived value from 
collaboration with the universities.  
 
 
Figure 8: Percentage of the firms in terms of university collaboration for 
technology development and innovation  
 
 
4.3.4 Intention of the firms to collaborate with universities 
 
Eighty-five percent of firms said they intend to enter into research collaboration with 
universities in the near future. This is illustrated in Figure 9. 
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Figure 9: Percentage of the pharmaceutical firms that intend to enter into 
research collaboration with the universities in the near future 
 
 
4.3.5 In-house research and development activities performance within firms 
 
Fifty-seven percent of firms are involved in ongoing in-house R&D activities, 24% 
have occasional involvement and 19% have never had in-house R&D activities 
(Figure 10).   
 
 
Figure 10: Percentage of the pharmaceutical firms in terms of the R&D 
activities performed in-house  
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 Innovation Management  4.4
 
This section presents the innovation management practices at the level of the 
pharmaceutical firms, in order to understand the process that the management 
personnel of these firms undertake to make decisions to form linkages with 
universities.  
 
 Search  4.5
 
The pharmaceutical firms conduct the process of search for university specialist 
knowledge (Figure 11). Thirty-four percent of the respondents mentioned that they 
undertake the search process by approaching the universities directly to seek 
scientific knowledge; while 26% conduct the search process through searching for 
existing patents and research publications and attending conferences (26%). The 
remaining respondents noted that that the search process is undertaken by using the 
firm’s knowledge brokers (9%) and conducting feasibility and market studies (6%).  
 
 
Figure 11: The scan and search process by the pharmaceutical firms 
participated in the study, (n = 35)  
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4.5.1 Value of search 
 
The pharmaceutical firms were asked if the search process adds value to their value 
for creation. Eighty-six percent indicated that the search process adds value to what 
they would want to create within their firms (Figure 12).  
 
The summary of the reasons from the respondents who indicated that the search 
process adds value for creation is shown in Table 4. 
 
 
Figure 12: Proportion of the pharmaceutical firms whose search process 
does/does not add value to their value creation 
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Table 4: Summary of the reasons from the pharmaceutical firms for 
conducting the search process, (n = 22) 
Reasons Frequency Relative 
frequency 
% 
Knowledge important to the company – 
develops expertise to become competitive 
relative to their competitors 
4 0.18 18 
Identify universities with relevant expertise  8 0.37 36 
To familiarise with what is happening in the 
research environment – to identify 
opportunities for collaboration and derive 
value 
7 0.32 32 
Build company’s internal database of the 
universities in order to inform strategy 
3 0.14 14 
 
 
4.5.2 Use of staff with specialised competencies for search process 
 
Pharmaceutical firms were asked if they use staff with specialised competencies to 
undertake the process of search. Seventy-six percent indicated that they use staff 
with specialised competencies to undertake the search process (Figure 13). 
 
 
Figure 13: Proportion of the pharmaceutical firms using and not using staff 
with special competencies to undertake the process of search 
Pharmaceutical companies that said YES to using staff with
specialised competencies in search process
Pharmaceutical companies that said NO to using staff with
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4.5.3 Factors considered in the search process 
 
This study explored an array of factors considered by the pharmaceutical firms in the 
search process. The summary of the factors as expressed in the order of importance 
is shown in Table 5. The most important and prioritized factors that the respondents 
noted were availability of resources at universities and the reputation of the 
university; university research complementarity to the firms and alignment to the 
company's strategy; university research with commercial potential and IP (intellectual 
property) confidentiality by universities; and cost implication for knowledge 
acquisition and public good.  
 
 
Table 5: Factors considered in the search process, (n = 44) 
Factors Frequency Relative 
frequencies 
Relative 
ranking 
Resource availability at universities for 
research and clinical research 
14 0.318 1 
Reputation of the university in the 
research frontier for doing and producing 
quality research including  commitment to 
deliver 
8 0.182 2 
University research complementarity to 
the firms and alignment to the company's 
strategy 
11 0.25 3 
University research with commercial 
potential and IP confidentiality by 
universities 
7 0.159 4 
Other factors including cost implications 
for knowledge acquisition and public 
good 
4 0.09 5 
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4.5.4 Types of projects 
 
Figure 14 represents the views of the respondents on the type of projects considered 
when conducting the search process. Thirty-four percent considered R&D projects 
with commercial potential, 31% indicated translational projects; clinical research 
projects (14.3%), research projects relevant to the market and are cost effective 
(11%) and projects with proof of concept (8%) when conducting search.  
 
 
Figure 14: Types of projects considered by firms in the search process,  
(n = 35) 
 
 
 Selection process  4.6
 
4.6.1 Factors influencing the selection process 
 
Several factors influenced the selection process for choosing universities other than 
other knowledge providers. Twenty-eight percent of firms agreed that expertise and 
experienced scientific know-how influenced their selection of the universities rather 
than other knowledge providers; and 15% said that reputation was an influencing 
factor. Conversely, 13% of firms agreed that the relevance and alignment of the 
university knowledge to firms’ research and innovation activities influenced their 
0
2
4
6
8
10
12
14
Translational
projects
R&D with
commercial
potential
Clinical
research
projects
R&D relevant to
market and
cost effect
Projects with
proof of
concept
Frequency Percentage
11 
12 
5 
4 
3 
31.4 34.3 14.3 11.4 8 
57 
 
selection process, while the other firms said that distance of the university in relation 
to firm’s location (at 11%), quality of the university research (at 11%), and 
infrastructure (e.g. research equipment) and a Technology Transfer Office availability 
(at 11%) at universities influenced their selection process. The remaining firms 
indicated that cost for knowledge acquisition (at 7%) and public utility (at 4%) also 
influenced their selection process. This is illustrated in Figure 15. 
 
 
Figure 15: Factors influencing the selection process, (n = 54) 
 
 
4.6.2 Characteristics of universities  
 
The characteristics of the universities influenced the selection process (Figure 16). 
Thirty-two percent of the firms agreed that universities with trained, experienced 
researchers with research expertise facilitate the selection process, while 20% of the 
firms indicated that universities with international exposure and standing among their 
research peers facilitate their selection process. Other firms noted that universities 
whose research is relevant to the firm, with technology platform infrastructure and 
are accessible to the firm, facilitate the selection process.  
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Figure 16: Characteristics of universities, (n = 41) 
 
 
 
 Decision making  4.7
 
4.7.1 Firm management level 
 
Figure 17 indicates the views of the firms on management level decisions on how 
knowledge collaboration with universities was taken. The graph reveals that 43% of 
decisions were taken by senior management, 40% were at Executive Level, which 
includes the CEO and 17% at Board Level.  
 
0 2 4 6 8 10 12 14
Trained and experience personell and
technical expertise
University research relevance to the
company
Good track record and reputation
International exposure and standing
Technology Platform infrastructure
Accessibility
Percentage Frequency
32 
14 
14 
20 
10 
10 
4 
4 
6 
6 
13 
8 
59 
 
 
Figure 17: Firm management level of decision making  
 
4.7.2 Investment committee  
 
Fifty-seven percent indicated that decision making involved participation of their 
investment committee (Figure 18).  
 
 
 
Figure 18: Proportion of the pharmaceutical firms with investment committee 
involvement in the decision-making process  
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4.7.3 Decision making process 
 
The pharmaceutical firms were asked to describe the process for making decisions 
on knowledge collaboration with universities. The summary of the decision making 
process is shown in Box 2.  
 
Box 2: Summary of the decision making process within the firms participated 
in the study 
 Process of iterative reasoning - for instance, is the knowledge aligned to the 
company's vision and is it cost effective? Gathering of all the data or 
information about universities’ scientific expertise and capabilities and patient 
population and reviewing universities’ past performance 
 Senior management providing inputs into strategic decisions 
 Thought process that goes into deciding which technologies to pursue for 
development and what knowledge inputs are required 
 Discussing the available treatments on markets such as their effects and 
demand, leading to decisions on projects to undertake 
 Discussing the commercial viability of the knowledge to the firm or whether 
the knowledge is commercially viable 
 Deciding what they require from universities and making decisions based on 
their requirements 
 Performing feasibility studies to determine which universities are potential 
collaborators. Also sending out questionnaires to universities to ask about the 
research they perform and the available expertise and if they would be 
interested in partnering on R&D 
 Discussing R&D strategy  with project managers  to determine whether 
knowledge is aligned to the company strategy 
 The CEO makes contact with universities about the research and then makes 
the final approval  
 Reviewing the firm’s past relationship with universities 
 Through collective efforts within different levels of the company 
 Consultation among different levels of the company 
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4.7.4 Decision approval  
 
Of the international firms operating in South Africa that were interviewed, 67% noted 
that the decisions are taken at their Head office overseas, 33% indicated that 
decisions are taken at the regional office in South Africa (Figure 19).  
 
 
Figure 19: Decision approval within the international pharmaceutical firms 
operating in South Africa participated 
 
In terms of where the operational aspect of knowledge collaboration is taking place, 
81% of the international firms noted that they had a Regional Office in South Africa, 
which was involved in operationalising the knowledge collaboration with the 
universities, while 19% said that their International Office got involved (Figure 20). 
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Figure 20: Operational aspect of multinational pharmaceutical firms for 
knowledge collaboration with the universities 
 
 
4.7.5 R&D projects decision making process 
 
A percentage of how the R&D projects were decided upon by all the pharmaceutical 
firms is indicated in Figure 21. Forty-one percent said that the outcome of market 
studies influenced which R&D projects or technologies were explored, and 22% 
noted that the decisions on which R&D projects to explore resulted from extensive 
discussions among the different departments within firms. Fifteen percent agreed 
that population studies dictated the decisions on which type and design of clinical 
research studies needed to be undertaken in collaboration with a university, and 
11% of the firms said that interaction with the relevant university department through 
a process of enquiry and a request from their overseas Head Office resulted in their 
decisions on which research projects to explore.  
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Figure 21: Decision making processes on R&D projects to explore, (n = 27) 
 
 
4.7.6 Management and improvement collaboration with universities  
 
Of all the pharmaceutical firms that participated in the study and indicated 
collaboration with universities (refer to Figure 4), 26% agreed that they managed 
improving collaboration with universities through capacity building and problem 
solving ability. This was followed by 15% of the firms that highlighted a commitment, 
sponsorships of conferences and constant searching for new and experienced 
people at universities and science councils to collaborate with the firm. Eleven 
percent all mentioned the mutual interest and benefits of collaboration, and search 
for new technical expertise, respectively, as important in managing improvement in 
collaboration with these technological knowledge providers. The remaining 7% 
mentioned that a constant communication helped to manage improving 
collaboration. This is indicated in Table 6.    
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Table 6: Managing knowledge collaboration with universities (n = 27) 
Managing knowledge collaboration Frequencies Relative 
frequency 
Percentage 
Capacity building and problem 
solving ability 
7 0.26 26 
Commitment to collaboration and 
relationships with Heads of 
Department. 
4 0.15 15 
Sponsoring and attending academic 
conferences 
4 0.15 15 
Looking for new people with expertise 4 0.15 15 
Mutual interests and benefits 3 0.11 11 
Constantly looking for new technical 
expertise 
3 0.11 11 
Constant communication 2 0.07 7 
 
 
4.7.7 Value of collaboration with universities  
 
All the pharmaceutical firms that collaborated with universities agreed that they had 
derived value from collaborating with universities (Table 7). 
 
Table 7: Views of the firms regarding value derived from knowledge 
collaboration with universities 
Universities 
Universities have much broader contracts which allow firm the freedom to 
collaborate with other actors. 
There are always students available in projects involving a firm collaboration. This is 
mainly facilitated by government funding programmes. 
Universities specializes in performing basic research, development and training of 
skilled human capital to support pharmaceutical firms research and technology 
development and have highly experienced researchers who understands markets 
needs for technologies. 
Conditions at universities are favourable for conducting clinical research activities by 
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firms, such as universities are connected to hospitals, enabling to have easy access 
to patients information and cooperation, and recruitment of quality patients to 
participate in clinical research.  
Universities understand markets and technology constraints as well as the South 
African regulatory requirements for clinical research. 
 
 Types of specialised university knowledge inputs 4.8
 
Figure 22 below indicates that 35% of the respondents from the pharmaceutical firms 
that participated agreed that research and related expertise is their knowledge 
requirement from the university to solve technology problems and constraints. 
Twenty-three percent of the respondents require research expertise that would 
improve production and manufacturing processes in order to increase their 
competitive advantage. Sixteen percent indicated they would require expertise to 
design a credible clinical research protocol that is cost effective. The remaining 3% 
require universities that would assist them in understanding the South African 
regulatory requirements for clinical research as well as on how to overcome such 
regulatory requirements.    
 
 
Figure 22: Types of university knowledge inputs required by the 
pharmaceutical firms that participated in the study, (n = 31) 
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4.8.1 Knowledge capture 
 
Figure 23 indicates the views of respondents from the pharmaceutical firms on ways 
their firms capture external technological knowledge inputs from universities to 
improve innovation process and deliver on projects. Fifty percent of the respondents 
capture technological knowledge on documentation of physical hard copies and 25% 
on electronic databases. Ten percent highlighted project management systems and 
technology transfer agreements to capture knowledge to improve collaboration 
experiences, respectively and 5% indicated that mentoring programmes assist in 
capturing knowledge for future projects.   
 
 
Figure 23: Capturing mechanisms for specialised knowledge inputs, (n = 20) 
 
4.8.2 Codification of external university knowledge 
 
Figure 24 shows the ways in which the firms codify external specialist knowledge 
from universities on physical and electronic base systems in order to benefit the 
innovation process of the firm.  
 
Thirty-eight percent of the respondents use electronic document systems, 33% use 
physical hard copies, 14% use training initiatives connected to manuals, and 10% 
and 5% used employment contracts and minutes of the meetings, respectively.  
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Figure 24: Codification of the external specialist knowledge from universities, 
(n = 21) 
 
 Learning from university knowledge inputs 4.9
 
Figure 25 shows how firms learn from external specialist university knowledge. 
Thirty-seven percent indicated that they learn from published research articles of 
interest during the search process of specialist knowledge, while 25% said that 
reviewing past research collaboration contracts with universities enable their learning 
experiences for future collaborations with external technology partners. Nineteen 
percent mentioned reviewing their firms’ internal databases of lists of universities 
including other electronic document management systems to facilitate learning. The 
remaining 13% and 6% agreed that mentoring of the firms’ researchers by university 
researchers on specific technologies and various training provided by the 
universities’ initiatives facilitate learning within firms.  
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Figure 25: Ways to improve learning from external university knowledge 
according to the pharmaceutical firms participated in the study, (n = 16) 
 
 
 
 
 Value of the university knowledge  4.10
 
4.10.1 Resource allocation to knowledge collaboration 
 
This section presents data on why the pharmaceutical firms dedicate resources to 
knowledge collaboration with universities. Thirty seven percent indicated that 
resource allocation to technological collaboration with universities helps to acquire 
knowledge in order to develop internal expertise on specific technologies for 
development and 33% spoke about the need to develop unique and competitive 
technologies (Figure 26). The remaining 30% collectively mentioned the need to 
develop their networks; to stay abreast of their competitors; to promote their 
company’s brand; part of the firm innovation strategy to form external collaborations; 
and to reduce costs for research and development, all at 5%.  
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Figure 26: Reasons of the firms for dedicating the resources to knowledge 
collaboration with universities, (n = 19) 
 
4.10.2 Effects of university knowledge on firm technologies  
 
Figure 27 summarizes the effects of how university knowledge has an effect on 
pharmaceutical firm research and technology development that participated in the 
study. University knowledge has an effect on pharmaceutical research and 
technology development. According to the below graph, 30% of the respondents 
mentioned that university knowledge helped to commercialise technologies faster; 
22% said that the effect of university knowledge was evident in increasing a firm’s 
technological knowledge and 17% mentioned the effect helped to conduct a highly 
competitive clinical research and enhanced the quality of the research, respectively. 
The remaining 4% agreed that university knowledge had an effect on making 
predictions of technology trends.  
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Figure 27: Effects of university knowledge on firms’ research and technology 
development, (n = 23) 
 
 
4.10.3 Effects of university knowledge on firm’s innovation  
 
Table 8 indicates the views of the firms on the effects of university knowledge on 
their firms’ innovation activities. Thirty-five percent agreed that university knowledge 
did not have any effect 18% said that it helped to increase a firm’s internal 
knowledge base, commercialised product technologies and designed clinical 
research protocols, 6% agreed that the university knowledge improved innovation on 
production and manufacturing processes for generic drug technologies, and effected 
the establishment of technology platforms at universities to focus on drug 
development initiatives.  
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Table 8: Effects of university knowledge on pharmaceutical firm’s innovation 
activities, (n=17) 
Effects of university 
knowledge 
on firm’s innovation activities 
Frequency Relative 
frequency 
% 
No effect 6 0.35 35 
Increases firm’s internal 
knowledge base to innovate 
3 0.18 18 
To commercialise product 
technologies faster through 
licensing 
3 0.18 18 
To design quality protocols to 
conduct clinical research 
3 0.18 18 
Improve innovation capability in 
manufacturing processes 
1 0.06 6 
Establish drug technology 
delivery programmes at 
universities 
1 0.06 6 
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 Summary of the key findings   4.11
 
4.11.1 Search process 
 
The pharmaceutical firms operating in South Africa that participated in this study 
employ a number of approaches to search for specialist technological knowledge 
from universities. These are: regular academic conference attendance; interactions 
with the relevant universities’ departments and technology transfer offices; patents 
and research publications; market studies and knowledge brokers. In addition, the 
pharmaceutical firms appear to search for external technological knowledge through 
student employment programmes which they had established, and use competent 
staff to search for specialist knowledge inputs from universities. They go out to the 
universities to find out which technologies are available that their firm can acquire 
and adopt.  
 
Although search adds value to the pharmaceutical firms, it seems to not be 
organised. It does not happen sequentially and is an “ad hoc” activity which is neither 
planned nor budgeted for.  However, the study suggests that search is effective and 
adds value to the firms as these are able to find the external specialist knowledge 
input from universities for their technology development and innovation activities. 
Search, therefore, adds value to the firm.  
 
The pharmaceutical firms consider an array of factors when conducting the search 
process. The key factors in the order of importance are: resource (experienced 
researchers and infrastructure linked to the research) availability to undertake the 
research; reputation of the university and commitment to produce deliverables within 
set timeframes and relevance of the university to firm strategy. It is also notable that 
upholding confidentiality of the intellectual property generated is also considered an 
important factor by firms when undertaking the search process. However, the cost 
implications to acquire university knowledge do not appear to be an important factor 
in the search process for external specialist knowledge; it was less frequently 
mentioned by the respondents compared to the other factors.   
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4.11.2 Selection process  
 
The pharmaceutical firms consider multiple factors to select universities among other 
technological knowledge providers. These are: expertise; experience, scientific 
know-how; relevance and alignment of the university knowledge to firms’ research 
and innovation activities; distance of the university in relation to the firm’s location; 
quality of the university research; and research equipment and Technology Transfer 
Office. Cost for knowledge acquisition and public utility play a minor role in the firm 
selection process.  
 
On the other hand, firms also take certain university characteristics into account 
when making their selection such as technology expertise, experience and know-
how, infrastructure and technology transfer office availability. The study suggests 
that these factors as well as the university’s characteristics may have influenced the 
selection criteria of firms for choosing the particular university among other 
technological knowledge providers, and ultimately the firm’s decisions in forming 
linkages with universities.    
 
4.11.3 Types of specialist knowledge inputs 
 
The pharmaceutical firms prefer university knowledge packaged in a commercial 
framework. This includes research related to the market and translational research 
leading to technology development. These firms seek out specialist knowledge 
related to the production and manufacturing processes. It is also noted that the 
pharmaceutical firms are interested in university knowledge that can assist them in 
understanding the regulatory environment for clinical research and for overcoming 
hurdles for new drug technologies approvals. The effects of these knowledge inputs 
could lead to the firms’ ability to commercialise their technologies faster and improve 
their competitiveness.  
  
The pharmaceutical firms capture the university knowledge inputs in internal 
knowledge management systems such as databases and programmes. These 
facilitate the firms’ learning process, which includes reviewing past research 
contracts with universities. Mentorship, i.e. working alongside highly experienced 
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researchers seems an important aspect of the learning experience in production and 
manufacturing processes as well as in designing clinical research protocols. 
Knowledge also flows to firms through licensing agreements and contract 
outsourcing. 
 
4.11.4 Decision-making and process 
 
In all the pharmaceutical firms that participated in the study, the decision to link with 
universities on research and development and technology development are taken at 
senior and executive management levels. Only a few decisions are taken at the 
company’s board level. However, the decision making process does not involve one 
individual, but is a participatory process involving a team of individuals from different 
business units within a firm. Decision making is iterative-- it is a thought process 
which is usually informed by feasibility studies, market information and patient 
population studies as well as interaction with universities to identify knowledge 
requirements. The decision-making process also involves investment committee 
inputs.  
 
In the case of international pharmaceutical firms operating in South Africa, the major 
and final decisions on knowledge collaborations, as well as clinical research based 
on new drug technologies, are approved at their Head Offices based overseas. The 
regional offices based in South Africa are mainly involved in the operational aspects 
of knowledge collaboration with universities, such as identifying the appropriate 
universities for collaboration on technology development and clinical research. They 
are, however, not necessarily involved in company policy and strategy decisions 
which are taken by the Head Office. Regional offices are required to provide regular 
feedback to the Head Office overseas regarding the progress of the research.  
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 Triangulation 4.12
 
The researcher also interviewed individuals from the South African universities and 
expert commentators that were drawn from the South African national government 
departments and government knowledge producing institutions. The individuals and 
expert commentators collectively will be referred to as participants in this section 
when presenting the data. The interviews were mainly to validate the views of the 
pharmaceutical firms that participated in the study from earlier interviews regarding 
linkages with universities on scientific and technological knowledge.  
 
This section, therefore, presents the combined views and opinions of the expert 
commentators separately in order to be able to assess their degree of congruence 
with those of the primary respondents, as well as any deviations from those views. 
The data is presented in tables of summary and graphs.  
 
4.12.1 Search 
 
All the participants agreed that the pharmaceutical firms perform the search function 
to ensure access to relevant specialised knowledge from universities. The views of 
the individuals and expert commentators with regards to search functions employed 
by pharmaceutical firms operating in South Africa for external specialist knowledge 
from universities is illustrated in Figure 28.   
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Figure 28: Search function by pharmaceutical firms operating in South Africa, 
(n = 23) 
 
 
 
4.12.2 Search process 
 
All the participants agreed that the process of search by pharmaceutical firms 
operating in South Africa is not organised but effective. Box 3 indicates the search 
process by pharmaceutical firms.  
 
Box 3: The search process in terms of the views of the expert commentators 
from universities and government departments and government knowledge 
generation institutions 
 Identifying a potential university partner on R&D at a local academic university 
conferences and then follow up to set up meetings for further discussions 
 Some pharmaceutical firms have in-house research programmes, therefore it 
becomes easier for them to engage the universities (which they have 
identified through on-line search for patents and academic publications and 
even at conferences) on potential collaborative research projects that would 
address their needs 
 Engaging the relevant universities that they had identified at conferences 
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 Pharmaceutical companies know their research needs  and approach the 
relevant university they believe would address these 
 Keeping abreast of the research developments at universities can be 
achieved through conference attendance, academic publications and patents. 
Pharmaceutical firms have governance structures comprising of scientific 
research board and stakeholders who provide advice. 
 
 
4.12.3 Sources of knowledge  
 
All the participants agreed that pharmaceutical firms have sources of knowledge to 
draw from. Table 9 indicates the typical sources of knowledge of pharmaceutical 
firms operating in South Africa in terms of the views of the expert commentators 
drawn from universities and government departments and government knowledge 
generation institutions who participated in the study.  
 
Table 9: Typical sources of knowledge of pharmaceutical firms, (n = 23) 
Source of knowledge Frequency Relative 
frequency 
% Ranking 
Publications and patents 
(prior art search) 
7 0.30 30 1 
Visits to universities 5 0.22 22 2 
Specialised university 
department and 
engagement 
4 0.17 17 3 
Conference proceedings 3 0.13 13 4 
Networks (word of mouth) 2 0.09  5 
Historical relationships with 
universities 
1 0.09 9 6 
University websites 1 0.09 9 
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4.12.4 Selection 
 
4.12.4.1 Selection criteria   
 
All the participants agree that pharmaceutical firms have criteria for choosing 
universities among other knowledge providers as opposed to science councils. 
Figure 29 reveals the criteria used by pharmaceutical firms to select universities for 
scientific and technological knowledge in the order of ranking.  
 
 
Figure 29: Selection criteria used by pharmaceutical firms for choosing 
universities among other technological knowledge providers, (n=24) 
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4.12.4.2 The characteristics of universities  
 
 
Figure 30: Characteristics of universities considered by pharmaceutical firms 
in the selection process, (n = 23) 
 
4.12.5 Types of linkages between firms and universities  
 
 
Figure 31: Types of linkages between firms and universities in South African 
pharmaceutical industry, (n = 40) 
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4.12.6 Nature of university scientific knowledge outputs  
 
The percentage of the participants who indicated the nature of scientific knowledge 
inputs needed by pharmaceutical firms operating in South Africa is indicated in 
Figure 32. Eighty percent said that pharmaceutical firms require scientific basic 
knowledge from universities packaged in a commercial framework and 20% said that 
firms require basic scientific knowledge from universities.   
 
 
Figure 32: Nature of university scientific knowledge outputs 
 
 
4.12.7 Types of knowledge flows 
 
All participants agreed that knowledge flows from universities to pharmaceutical 
firms through a variety of channels or flows as indicated in Figure 33. These include 
contract research (frequency = 1), outsourcing (frequency = 1), employment of 
experienced researchers (frequency = 2), as well as interactions or engagement with 
the university research departments (frequency = 4) and license agreements 
(frequency = 2).   
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Figure 33: Types of knowledge flows, (n = 10) 
 
 
4.12.8 Influence of knowledge flows 
 
Box 4 indicates the influence of knowledge flows on pharmaceutical firms’ innovation 
activities, according to the views of the expert commentators drawn from universities 
and national departments and government producing knowledge institutions. 
 
Box 4: Influence of knowledge flows on pharmaceutical firms’ innovation 
activities 
 Create innovations in product technologies 
 Adopt new technologies from universities and develop innovation 
 Help pharmaceutical firms to focus on research in order to address 
their technology needs and deliver on new technologies that might 
create competitive advantage 
 Enhance capacity within pharmaceutical firms to innovate 
 Increase pharmaceutical firms’ potential to compete on the market 
 Further the research focus within pharmaceutical firms 
 Develop technology platforms  focusing on drug discovery projects 
 Reduce costs for doing research within pharmaceutical firms 
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Universities are perceived cheaper by the pharmaceutical firms 
 Assist the pharmaceutical firms to gain insight and understanding - so 
to do research differently. 
 Make decisions on research projects that would lead to incremental 
innovation 
 
 
4.12.9 Cost effectiveness 
 
All participants agreed that cost effectiveness is important to pharmaceutical firms 
when acquiring technological knowledge from universities. This is indicated in Box 5. 
 
Box 5: The importance of cost effectiveness of the university knowledge 
acquisition by the pharmaceutical firms 
 Most pharmaceutical firms’ technological capabilities enable them to 
make decisions on selection of appropriate universities to form linkages 
with 
 The R&D budgets of pharmaceutical firms are small or limited-- about 
R2.5 million. As such, pharmaceutical firms are interested in 
collaborating with universities to advance their research budget. 
 Knowledge acquisition supports pharmaceutical firm strategy 
 Pharmaceutical companies have research strategies with identified 
research areas of focus. They utilise university linkages to identify 
highly experienced researchers whom they can employ in the future 
 Knowledge flows save the pharmaceuticals time in research and 
innovation process 
 
 
 
4.12.10 Reasons for pharmaceutical firms for choosing universities 
 
The participants indicated that pharmaceutical firms have reasons why they are 
choosing universities as external specialist technological knowledge. Box 6 indicates 
the summary of the reasons in terms of the views of the participants. 
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Box 6: The reasons of pharmaceutical firms for choosing the universities 
 Universities have partial full cost models which do not entail labour and 
overhead costs as compared to science councils – having full cost model for 
R&D 
 Pharmaceutical firms have a history of relationships with universities which 
have been built over time and know what research is being performed at 
universities.  
 Universities produce quality of research linked to students. Students can be 
employed by the pharmaceutical firms for research work. 
 It is cheaper to collaborate with universities than science councils, for 
example. 
 Working with universities gives pharmaceutical firms the credibility and 
enhances their reputation 
 To take advantage of research funding opportunities at universities 
 
This data were used in this study to get additional insights and achieve a higher 
degree of reliability of the primary data collected from the initial elite interviews with 
the pharmaceutical firms operating in South Africa.  Triangulation was included to 
compensate for the small sample size of the pharmaceutical firms that were studied 
in this research project. 
 
It was observed that there is a high level of correspondence between the views 
expressed by the pharmaceutical firms and those of the individuals drawn from the 
selected universities and government knowledge generation institutions and national 
departments, with minor variations in some instances. The general validation of the 
views of the pharmaceutical firms regarding the types of linkages with the 
universities, search processes and the selection criteria was observed. These can 
enhance our understanding of the nature of the management decision-making 
process within the pharmaceutical firms operating in South Africa. 
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5. CHAPTER 5: ANALYSIS OF FINDINGS 
 
 Introduction 5.1
 
This chapter presents an analysis of the key research findings of the study. The 
chapter is organised to address the two research questions: (a) What are the types 
of linkages between the pharmaceutical firms that participated in the study and 
universities? (b) How do the pharmaceutical firms that participated in the study make 
decisions which university to form linkages with?  
 
The study uses data collection from the pharmaceutical firms operating in South 
Africa that participated in the study, and triangulation. The data collection from the 
pharmaceutical firms was obtained by interviewing senior executives and managers 
from the study cohort of local and international pharmaceutical firms operating in 
South Africa.  Data was gathered from interviews with respondents who worked as 
senior scientific and technology researchers and senior technology transfer 
managers at South African universities. Furthermore, triangulation included 
interviews with expert commentators from the South African government 
departments and knowledge generation institutions owned by the South Africa 
government. These included senior consultants, technology commercialisation 
managers and directors. The data was analysed together with the information 
gathered from earlier interviews with the pharmaceutical firms that participated in the 
study.  
 
The analysis of the findings obtained from the pharmaceutical firms and triangulation 
are integrated to create a coherent argument.  
  
 Types of linkages between firms and universities  5.2
 
Edquist (2001) asserts that the innovation systems approach is a framework to 
understand and identify innovation policy issues. One of the issues identified in 
innovation policy is interactions across and between firms and other actors within the 
innovation system such as universities. The scholars from the system of innovation 
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perspective all argue that firms across industrial sectors do not innovate in isolation 
but do this through interacting with other actors, such as universities, financial 
institutions, governments, industrial networks and other organisations such as non-
governmental organisations, whose roles are the production, dissemination and 
diffusion of knowledge to create innovation outcomes (Freeman 1982; Edquist 1997, 
2001; Fischer 2000; Ludvall 2004). The types of interactions are shaped by a variety 
of factors such as social, political and institutional laws (Edquist 2001).  The literature 
mentions that firms form interactions with these agents in order to harness their 
learning and technological capability building in order to encourage innovation 
(Adams, Bessant and Phelps 2002 citing Tidd, Bessant and Pavit 1997). 
 
Linkages between universities and firms are a relatively new phenomenon in the 
South African context especially from the perspective of firms. However, different 
types of linkages have been studied within the context of South Africa, focusing on 
the perspective of universities within technology-intensive industries. This was 
mainly to understand the view of universities in forming linkages with highly 
technology-intensive firms, with a view to making universities respond to addressing 
the economic and social needs of the country through policy measures (Kruss 
2005a, 2005b).  
 
According to Kruss (2005a, 2005b), linkages are defined as knowledge networks, 
partnerships and even collaborations between universities and firms that are of 
mutual benefit to both. In view of this definition, scientific and technological 
knowledge flows both ways and is diffused through different channels in order to 
promote learning (Morondi 2011, citing Das and Teng (2000). Ryall and Sampson 
(2003) state that from the perspective of firms, the main purpose of linkages is to 
enable access to and the acquisition of complementary assets, technology, sharing 
of research costs, mitigate risk of innovation and enter new markets, and a range of 
other benefits. Kruss (2005a) and Smith and Katz (2000) cite that linkages have 
multiple intentions and meanings and can be developed at various levels – such as 
individual, group and research departments, sectors and country and in complex 
environments, probably characterised by technological change, market dynamics 
and competition to name a few. Linkages have become innovation strategy by firms 
to overcome these complex environments (Castells and Cardoso 2005). According 
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to Kruss (2005a), the formation of linkages between universities and firms in 
technology intensive industry are influenced by forms of universities and their 
historical legacy, uneven research capacity, institutional capacity and financial base 
and shaped by financial and intellectual imperatives driving both firms and 
universities to form linkages. What is needed is the conscious decision at the 
governmental level, through sound policy options and programmes, to promote the 
desirability of linkages between universities and firms, in order to make universities 
and firms part of the system in contributing to the economic and social development 
of South Africa.      
  
The South African government, through the Department of Trade and Industry and 
National Department of Science and Technology established the THRIP (Technology 
and Human Resources for Industry Programme) (refer THRIP website 
http://thrip.nrf.ac.za). According to the THRIP website (http://thrip.nrf.ac.za), the 
purpose of THRIP is to promote linkages between firms and universities across 
technology-intensive industries such as the pharmaceutical industry, through 
incentives and funding in order to address the shortage of technological knowledge 
and skills for firms and respond to general socio-economic challenges. Since the 
operationalisation of the THRIP Programme, different types of linkages have been 
formed between firms and universities, which have been studied and cited in 
empirical studies in specific technology sectors such as biotechnology in terms of 
their benefits and risks (Kruss 2005a, 2005b, 2012). 
 
Kruss (2005a, 2005b) developed an analytical framework, which distinguishes 
typologies of linkages, to provide an understanding of the different types of linkages 
between firms and universities in high technology industries. The typologies are: 
donations and sponsorship, commercialisation; consultancy and contract, and 
incentive and collaboration. The framework is applied to provide an analysis of the 
types of linkages revealed in this study between firms and universities in the South 
African pharmaceutical industry. Kruss (2005a, 2005b) argues that these are shaped 
and defined by the motivations of firms and universities to form linkages, and 
strongly associated with specific benefits and risks for innovation (Kruss 2012).  
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‘Donation’ has been described as the oldest form of linkages in South Africa and 
from the perspective of firms, has been conceptualised as benefaction or 
philanthropy. It is closely related to a sponsorship type of a linkage. Through this 
type of a linkage, a firm provides funds to universities to execute a research project 
that would help firms to address technology issues, develop new products, enter new 
markets, and attain overall competitiveness. Donations and sponsorships for 
research help firms to develop competitive advantage in relation to competitors. 
Examples of linkages in this typology include postgraduate student research, 
conferences, and post graduate studentships.  
 
Consultancies are the most dominant type of linkages in South Africa and motivated 
by universities’ financial need for R&D. In consultancies, a university researcher 
provides technology services in the form of advice to a firm. Furthermore, 
universities may provide a firm with training or mentorship on a specific technology. 
Contracts are closely related to consultancies and tailored to solving research 
problems of firms. Firms choose universities with the appropriate technological 
expertise, experience, capacity and research infrastructure and equipment to provide 
consultancy services, through contractual agreement, in order to deliver on research 
objectives within an agreed timeframe. The disadvantage of consultancies to 
universities is the restriction to pursue their research agenda in exchange for the 
protection of the financial interests of industry. 
 
Collaboration is viewed as the most traditional form of linkage between firms and 
universities in South Africa. This type of linkage is motivated by the intellectual 
strategies of the university and proactive strategies of firms and more likely to be bi-
directional. In this view, technological knowledge and other inputs flow two ways and 
there is a high potential for learning taking place between firms and universities. 
Examples of linkages include joint R&D projects, networks and science parks, as 
well as hiring post graduate students, conferences and publications. 
 
Commercialization is the emerging form of linkage between firms and universities in 
South Africa, mainly driven by the economic strategies of universities and the 
proactive strategies of firms. These types of linkages usually take the form of spin-off 
companies or incubators and require personal interactions. Most firms in highly 
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technology- intensive industries prefer universities that display entrepreneurship in 
R&D activities and are able to protect and manage intellectual property 
appropriately. Such universities are characterised by the presence of Technology 
Transfer Offices. 
  
The responses from the pharmaceutical firms as well as from individuals from 
universities and expert commentators who participated in this study are typical types 
of linkages that would be found in high technology-intensive industries including the 
pharmaceutical industry. The research findings also correlate with the findings 
obtained by Kruss (2012) for firms and universities in the biotechnology industry. The 
pharmaceutical and biotechnology industries are closely related in their nature. While 
this study supports the findings of Kruss (2005a, 2005b, 2012), it further suggests 
that knowledge flows to and from firms and knowledge producing institutions, and 
influences the firms’ innovation activities by helping them to focus on research that 
would address technology issues and deliver products that would create competitive 
advantage. This study suggests that these types of linkages were created to benefit 
the pharmaceutical firms that participated in the study in providing the firms with 
intellectual abilities in technology development and innovation activities (Kruss 
2012), as well as building learning capabilities.  
 
Furthermore, the findings of this study corroborate the findings of Siyanbola and co-
authors in their study of the type and intensity of linkages between firms and 
universities in the Nigerian pharmaceutical industry using a survey of 25 
pharmaceutical firms operating in Nigeria (Siyanbola et al 2012). These authors 
found that consultancy, staff exchange and fellowship programmes and sponsored 
workshop participants are the most common types of linkages. Similar findings were 
also obtained by Parahons (2009) in the Brazilian pharmaceutical industry using a 
quantitative research methodology in the form of a survey.  
  
 Effectiveness of the decision-making process 5.3
 
Kofinas and Saur-Amaral (2008) describe the pharmaceutical industry as research 
intensive, and its competitiveness depends on continuous inventions and 
innovations. The ultimate embodiment of knowledge creation in the pharmaceutical 
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industry is the successful commercialization of new drug technologies which 
represent the key competitive factor for the industry. 
The Business Monitor Report (2009) as well as the South African Department of 
Trade and Industry Report profiling the South African pharmaceutical industry (2011) 
stated that the South African pharmaceutical industry is faced with several 
challenges, which make it not respond effectively to addressing the health needs of 
the population. These challenges include a declining share of the South African 
pharmaceutical market as a percentage of the global market, unpredictable 
consequences of the price control of medicines and measures to contain the fast-
rising cost of public healthcare, ever changing regulations for drug approvals and 
clinical research conduct, closing down of manufacturing plants for drug technologies 
resulting in loss of manufacturing capabilities and lowering costs of conducting 
research and development.  
 
In view of these reports, what is needed in the South African industry, especially at 
the level of firm, is executive and senior management to consider decision making 
processes as part of innovation management in order to respond more effectively to 
industry challenges and tackle organizational complexity and multiple marketplace 
demands. Decision-making effectiveness ought to be regarded as a crucial 
complementary asset along with other capabilities enabling decisions to seek 
external specialist technological knowledge providers. 
 
5.3.1 Searching 
 
The search function is an important aspect of innovation management at the firm 
level (Tidd and Bessant 2009). Cited by Laursen and Salter (2004), Katila and Ahura 
(2002) and Mahdi (2003) firms search for new product ideas and solutions to existing 
technological problems. Based on this view, firms conduct search in order to identify, 
process and select knowledge (e.g. scientific and technological knowledge) from the 
environment that would trigger innovation process; and to create new knowledge 
(Purcell and McGrath 2013). This gave rise to the following question: How do 
pharmaceutical firms operating in South Africa that participated in this study search 
for technological knowledge and other inputs from universities? 
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The study suggests that these firms perform the search for technological knowledge 
and other inputs from universities through patent searches using their own patent 
search engines; consulting or making regular contacts with researchers at 
universities in meeting settings to find out the kind of research universities are doing, 
for instance, whether the research is relevant to the firm, is aligned to the company’s 
strategy, is cost effective and can be applied to developing technologies that can be 
commercialised; regular attendance at local conferences hosted by universities to 
find out developments in the research environment, create networks and identify 
potential research partners; consulting technology transfer offices located at 
universities to find out what technologies are available; using their own knowledge 
management systems such as a database of the list of universities and review 
reports of past collaborations with universities; conducting feasibility studies and 
market analyses to search for any signals in the environment.  
 
Furthermore, all the participants drawn from the universities and national 
governments and government-owned institutions of knowledge generation agree that 
the pharmaceutical firms operating in South Africa search for technological 
knowledge and other inputs by using a “word of mouth” strategy. This referred to 
sharing of important and useful information among the firms which could be applied 
in the innovation process activities as all participants agree that firms attend 
academic conferences to search for technological knowledge. The views of the 
respondents from universities and national government departments and 
government-owned knowledge generation institutions indicated that the 
pharmaceutical firms use academic publications to find out developments with 
research, and to identify researchers and affiliated institutions; calls for proposals to 
identify research that is aligned to the firm strategy that the firm can fund; and 
student recruitment to attract and employ research with talent.  
 
The study provides an insight that the pharmaceutical companies make use of 
people with specialist competencies to undertake the process of search and scan 
functions. These are boundary agents whose role is to go out to interact with 
universities to identify opportunities for technological development and innovation for 
firms and to communicate such information to the firm (Salas 2009 citing Allen 
1977), with possible consideration for the acquisition of technological knowledge and 
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other inputs. This viewpoint was confirmed by the respondents, who indicated that 
the pharmaceutical firms’ use of people with specialist competencies becomes 
evident since these people had been exposed in the research environment through 
previous post graduate studies.  
 
The study suggests that the search process employed by the pharmaceutical firms is 
organised and adds value to what firms wish to create, which is improved and or new 
technologies and even production and manufacturing processes. While this was 
supported by the respondents from universities and expert commentators drawn 
from the national government departments and knowledge producing institutions, the 
findings further suggest that search helps the pharmaceutical firms to keep abreast 
of the nature of the research being performed at universities and also how to apply 
technological knowledge and other inputs to improve decision-making effectiveness. 
According to Laursen and Salter (2004), the search strategies employed by firms in 
technology intensive industries such as pharmaceuticals, coupled with investment in 
R&D, pre-empt the ability to draw external technological knowledge from universities. 
This is crucial for management decision making in shaping the propensity of firms to 
seek technological knowledge and other inputs from universities. This suggests that 
the pharmaceutical firms would have developed internal capabilities also known as 
complementary assets over time coupled with a strong research component to 
enable firms to use external technological knowledge and other inputs from 
universities effectively (Marcelle 2011).  
 
Given the nature of the South African pharmaceutical industry, which is technology-
intensive and requires external knowledge for competitive advantage, there are 
particular projects and types of knowledge required by firms from universities in 
order to increase their competitive advantage. For this reason, the firms within the 
pharmaceutical industry have in general been resilient and competitive in producing 
drug technologies to improve the quality of health of the South African society and 
even on the African continent (through export).  
 
The study suggests that the participating firms operating in the South African 
industry required university knowledge packaged in a commercial framework during 
the search process. While this viewpoint is supported by individuals and expert 
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commentators from universities and national government departments and 
knowledge producing institutions, the findings further suggest that the university 
projects that have progressed downstream in the value chain are considered during 
search process, and decision making processes. According to the Research Report 
on South African Manufacturing of Pharmaceuticals compiled by Mahomedy (2010), 
the university research that has progressed downstream in the value chain 
stimulates pharmaceutical technology development and innovation to develop drug 
technologies to address pressing disease areas facing South Africa and the African 
continent such as HIV and AIDS, TB and malaria and other infectious diseases.  
Furthermore, university knowledge related to R&D and knowledge in technology 
development and process manufacturing helps pharmaceutical firms to solve 
problems in production or manufacturing processes, as well as to make 
improvements on old or completely new technologies as these will increase changes 
of technology or product commercialisation. 
 
5.3.2  The factors in the search process  
 
According to the literature, there are a variety of factors which could influence a 
firm’s search process for technological knowledge and other inputs from universities. 
The factors may include firm size and R&D budget (Laursen and Salter 2003). These 
factors could shape how management makes decisions on the type of attributes they 
are looking for in a potential external partner for the establishment of linkages. The 
results indicate that among the factors found in this study, the resources available at 
universities for research and clinical research, such as experienced researchers in 
R&D and clinical research, research equipment and research laboratories, the 
reputation of the university in the research frontier for doing and producing quality 
research including commitment to deliver, are the most significant factors in 
searching for knowledge from universities. The empirical literature on studies of 
industry-university linkages, which focus on the determinants and motivation for 
collaboration in the case of the firms, suggest that reputation and quality of university 
research are responsible for the formation of linkages between firms and universities 
across sectors and contribute to the success of the collaboration (Mora-Valentin, 
Montoro-Sanchez and Guerras-Martin 2009). Other factors found by the present 
study include university research complementarity to the firms and alignment to the 
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company strategy; university research with commercial potential and intellectual 
confidentiality by universities as well as cost implications for knowledge acquisition 
and the public good provided by the universities. Strikingly, pharmaceutical firms are 
not looking for cost-effective knowledge acquisition from the universities for their 
production and manufacturing processes. This implies that cost is not a decisive 
factor for pharmaceutical firms when deciding on whom to collaborate with.  
 
In summary, pharmaceutical firms operating in South Africa are involved in a search 
process for external knowledge at universities and are able to recognise signals in 
the marketplace. This implies that firms have a degree of knowledge and capabilities 
related to R&D and technological development built over time, which enable them to 
recognise the knowledge they need for innovation.  
 
5.3.3 Selection of universities 
 
5.3.3.1  Factors influencing the selection process 
 
According to Lundvall (2004), the key agents are firms and public research 
organisations, also known as “science councils” in South Africa, and universities 
whose role is to create and disseminate knowledge to firms to create innovations. 
Based on this view, firms across technology-intensive industries are therefore 
exposed to a variety of possibilities and options from which they can access and 
acquire external technological knowledge for innovation outcomes and competitive 
advantage, as firms are faced by ever increasing competitive pressures (Hung and 
Tang 2008). Based on the work of these authors, firms need to develop strategies 
that would allow then to gain new technologies from external sources in order to 
initiate their own innovation processes leading to improved production processes.  
 
However, Tidd and Bessant (2009) make a case that the challenge facing the 
management of firms is how to choose among a variety of options for external 
technological knowledge and other inputs. Tidd and Bessant (2009) further argue 
that in order for firms to choose among external technological knowledge, they need 
to develop criteria which articulate how innovation can help them survive and grow in 
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competitive technological markets and develop competitive advantage in relation to 
competitors.  
 
Rothaermel (2001) conducted a quantitative study of how pharmaceutical firms 
select alliances from the population of biotechnology start-up companies in their 
quest to seek technological knowledge to commercialise their products. The findings 
of Rothaemel (2001) study suggested that the pharmaceutical firms select the new 
biotechnology start-ups based on new technologies and stages of development, 
economic of scale (cost effectiveness), public ownership and geographic location of 
start-ups in relation to the firms. Rothaemel (2001) argues that these selection 
attributes make the biotechnology start-up companies more attractive to form 
alliances as opposed to other knowledge providers. 
 
Although the study of Rothaemel (2001) focused on firm to firm linkages, the findings 
of the present study suggested that the factors that influenced the decisions of the 
participating pharmaceutical firms operating in South Africa to select universities are 
more likely when there is an intention to develop technologies to the point of 
commercialisation. The universities which have good reputations, perform quality 
research relevant to the firms’ technology development and commercialisation 
needs, and those based in close proximity relative to firms are likely to be preferred 
for collaboration by the participating pharmaceutical firms. The findings of this study 
are in agreement to studies conducted on motivations or the propensity of firms in 
technology-intensive industries where the quality of research, geographic location 
and reputation increased the likelihood of firms to form collaborations with 
universities.  
 
5.3.3.2 Characteristics of universities  
 
Universities are important agents in creating knowledge which is an important source 
of innovation at the firm level. According to Sbuwufu, Ludwick and Beland (2012), 
universities, especially in developing countries, are being positioned by national 
governments as strategic assets in innovation and economic competitiveness, and 
as problem-solvers for socio-economic problems affecting their countries. However, 
these authors argue that in order for countries to fully capitalise on the value of 
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universities in addressing their socioeconomic issues, governments and institutions 
need to actively pursue policies and strategies that would create conditions for the 
development of university linkages with industries. 
 
The mandate of universities explicitly requires that they undertake upstream R&D, 
produce human resources and contribute to addressing socioeconomic challenges. 
In the South African context, many universities are now setting up Technology 
Transfer Offices, establish technology platforms and in some cases establishing 
incubation centres as a way of making themselves attractive to firms for the 
formation of linkages on R&D, and technology development. For this reason, 
universities in South Africa have over many years been gradually building 
institutional capacity through the production of experiences and skilled human 
resources and research infrastructure, to gain overall competitiveness. 
 
This study suggests that universities with trained and experienced research 
personnel and technical expertise are the main considerations of the participating 
pharmaceutical firms for selecting universities for the formation of linkages. This 
finding is, however, contradictory to the findings of Giuliani and Arza (2008) in the 
wine industry in Chile using a qualitative research methodology on managers of the 
firms. The authors argued that the quality of the research related to experienced 
researchers who conduct the research at university departments does not influence 
the firm’s decisions to select universities based on this characteristic. It is therefore 
very important to take context into account in order to understand the relationship 
between the quality of research and the firm’s selection process with the likelihood of 
the formation of linkages from the perspective of firms.  
 
In this study, firms further indicated that they would select universities whose 
researchers have good reputations linked to international exposure and standing 
among their local and international peers. Dollinger et al (1997) argue that the 
reputation, which is information about the partners that is publicly known by the rest 
of the agents taking part in a given sector or activity (Mora-Valentin, Montoro-
Sanchez and Guerras-Martin 2004), may expose the characteristics of universities 
concerning management, the quality of their products or financial status to the 
potential firms that wish to form linkages. This study suggests that the firms would 
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select universities for forming collaborations, which conduct quality research and that 
is relevant, and have experienced researchers who are highly respected in their area 
of research which is relevant to the firm’s core business and strategy.  
 
Accessibility in this case, can be framed in terms of the geographical proximity of the 
location of the university. It is referred to as the distance between a firm and 
university and often measured in kilometres. Thus, accessibility can be explained in 
terms of the value of direct and interpersonal contacts, primarily to acquire tacit 
knowledge and access to new research. Arundel and Geuna (2003) argue that 
geographical proximity has an effect on firms’ ability to access tacit knowledge for 
innovation. The authors make a case that the public research organisations, 
including the universities’ knowledge flow, can make a substantial contribution to firm 
innovation. In other words, geographic proximity favours knowledge flows from 
knowledge producers to the innovators such as firms. The present research 
suggests that the pharmaceutical firms that participated in the study would select 
universities that have closer proximity in order to facilitate knowledge flows and 
access to knowledge. It can be assumed that the accessibility of university 
knowledge is important to a firm’s desire to produce new products at least for the 
manufacturing pharmaceutical firms interviewed. Empirical research supports this 
finding and suggests that the closer the university is to the firm in a developing 
country context, the more the knowledge is accessible to the firm and can encourage 
cooperation between academic and firm R&D staff (Garcia et al 2014). 
 
5.3.4 Firms’ management hierarchy of decision-making 
 
Senior executives and managers were asked to indicate where decisions regarding 
knowledge collaboration with universities are undertaken. Knowledge collaboration in 
this case, refers to R&D and clinical research. The latter encompasses access to 
patients’ medical history and recruitment of patients to participate in clinical research. 
 
This study found that the majority of the decisions are undertaken at the behest of 
the board, senior executive (including CEO) and senior manager’s levels. It is 
observed that most decisions are taken by the senior executive including the CEO 
and managers. However, few pharmaceutical firms had indicated that the decisions 
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are taken by the board members of the company. This finding is not surprising since 
board members mainly pay attention to decision-making that involves and influences 
organisational direction, administration and structure (Naghibi and Baban 2011) 
rather than the operational aspects of the firm. It is also notable in this study that 
most of the decisions regarding knowledge collaboration with universities are taken 
by senior managers who are involved in the operational aspects of the knowledge 
collaboration with the universities.  Schmidt and Buell (2014) mention that senior 
managers (including senior operation mangers) in business environments that 
require introduction of new product technologies into the market are required to 
make the decisions that would ensure long term sustainability and performance.   
 
Senior managers are responsible for the implementation of strategic decisions that 
are taken at CEO level and ensure that the appropriate university is identified and 
contracts are signed and collaboration is established. In other words, they are the 
ones who interact with and engage the universities in meetings, in order to identify 
the university knowledge relevance to drive the firm strategy for R&D processes. 
Senior managers are accountable to the CEO and are very careful in the choice of 
university research partners. This finding of the present research is in alignment with 
the view of Arasa and K’Obonye (2012) citing Hofer and Schendel (1978) that 
operational decisions involve an evolution of environmental changes in relation to a 
changing company’s internal structures and production processes as well as 
efficiencies, and managers should be able to integrate such changes with 
organisational strategy and structure in order to achieve innovation and 
performance.  
 
This research found that decisions on identifying universities on R&D partnership 
with universities are not taken with the involvement of the investment committee. 
This is rather surprising since taking decisions could be a complex process and 
inherently risky and may have a negative impact on the future of the organisation (Al-
Tarawneh 2012). Hence, the involvement of committees to provide 
recommendations on the appropriate decisions would be expected. However, there 
were pharmaceutical firms that indicated the involvement of their investment 
committee. These were the international companies operating in South Africa and 
whose main offices are based in developed countries. The results obtained from this 
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study revealed that the parent pharmaceutical firms based in developed countries 
approve the decisions regarding knowledge collaboration made by their firms 
operating in South Africa. This indicates that there is a threshold for decisions that 
get made by the pharmaceutical firm operating in South Africa. Although the parent 
pharmaceutical firm approves the decisions made by firms operating in South Africa, 
they are not involved in the implementation of the decisions or operationalization of 
knowledge collaboration.   
 
5.3.5 Decision-making processes 
 
This research discusses the nature of the management decision-making processes 
used by the pharmaceutical firms, as they form linkages with specialist providers of 
technological knowledge and other inputs such as universities. According to the 
Industrial Policy Action Plan (IPAP) of South Africa (2014), the pharmaceutical 
industry is among the industrial industries to contribute to economic growth and job 
creation in South Africa (IPAP 2014). Furthermore, the pharmaceutical industry is a 
strategic sector within the country’s innovation strategy and universities are also 
recipients of public support for R&D.  
 
In South Africa, firms in the pharmaceutical industry have the option to seek 
specialist technological inputs from other firms, publicly funded research councils 
and from universities. According to IPAP (2014), the pharmaceutical industry has 
been experiencing a number of challenges and constraints to realise growth and 
development including loss of manufacturing capabilities. Nonetheless, 
pharmaceutical firms have strong linkages with public research institutions including 
universities and seek out these relationships in order to have access to scientific 
knowledge, know-how, and research equipment in order to build their own 
capabilities for technology development and attain a competitive advantage relative 
to their competitors (Al-Bader et al 2009, Kruss 2012). These studies report that the 
firms experience a number of challenges when collaborating with the universities, 
including lack of commercial knowledge, prolonged intellectual property negotiations 
and unrealistic expectations in terms of royalties generated from the commercial 
exploitation of their research.  
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The decision making processes have been described as iterative and incrementally 
facilitated by relevant and even irrelevant factors over time (Teal 2011). They are 
part of the firm’s innovation strategy which enables firms to build deep stock of 
complementary assets over time including financial, physical, natural, intellectual, 
human, and social capital (Marcelle 2011), as well as to enhance a firm’s innovation 
management effectively. According to Marcelle (2011), decision making processes at 
firm level are referred to as implementation steps that seek to search for resources 
and apply these in ways that add value and generate advantage over competitors 
(Marcelle 2011). The resources are linked to the nature of the production and 
consumption process in the industry in which the firm operates and also to factors 
such as the lifecycle of the technologies in use, and socio-economic conditions in 
which the firm is embedded. 
 
This study deduced that the nature of the decision making processes within the 
participating pharmaceutical firms is one of the strategic imperatives for sourcing 
external technological knowledge and other inputs from universities for technology 
development in manufacturing and production processes and even clinical research. 
The study therefore suggests that decision making processes on knowledge 
collaboration with universities within the pharmaceutical firms are informed by 
information and data collection from decision making influences such as search and 
selection processes, as well as consultation processes. The information and data 
collection is done during search and selection processes about universities’ scientific 
expertise and capabilities and patient population and reviewing universities’ past 
performance and the participating firms use this information to inform their decisions 
on forming linkages with the universities on research and technology development. 
The respondents from the participating firms mentioned that the decision making 
process is iterative, which means the information goes through a process of analysis 
to assess its alignment with the firm strategy. According to Accenture (2008), the 
decision making processes that have been informed by empirical data and factual 
information by the life science-based industries including pharmaceutical industry are 
used to compare organisational effectiveness and culture with the market norms. 
 
Ideally, firms in technology-extensive industries such as pharmaceutical firms usually 
adopt tools and frameworks to help senior managers and executives to assess the 
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decision making effectiveness in order to achieve high performance and competitive 
advantage in relation to their competitors (Accenture 2008). However, this study 
shows that the decision making process of the participating pharmaceutical firms 
were iterative but not based on the adoption of tools to assess the comprehensive 
nature of the decisions as participating pharmaceutical firms were forming linkages 
with universities on R&D and technology development. These findings are contrary 
to the processes followed by the North American pharmaceuticals in evaluating 
decision making processes to improve its decision making processes in order to 
respond more effectively to competitive pressures and tackle organizational 
complexity and multiple marketplace demands. Accenture (2008) makes a case that 
the decision making processes and frameworks of the North America pharmaceutical 
firms were comprehensive, encompassing strong leadership involvement of the firm 
in providing understanding of the organisational complexities and culture; the use of 
decision making effectiveness diagnostic tools such as culture value analysis to 
review the firm’s organisational culture and benchmarking with good practices, 
decision making mapping to quantify the cost of making decisions, labour risk, value 
and time, and organisation network analysis to understand how decisions really get 
made. Based on this view, it is deduced that the participating pharmaceutical firms’ 
decision making processes were not holistic and comprehensive in order to provide 
understanding of the decision making processes as they form linkages with the 
universities. Furthermore, the decision making processes were improved and 
became effective as these firms were able to identify external opportunities, develop 
methodologies and tools for making further assessments and set metrics to quantify 
the attainment of business objectives.  
 
This study suggests that the decision making processes are critical and should be 
holistic and comprehensive involving other business dimensions such as firms’ 
leadership and culture. There is therefore an oversight of these important 
dimensions, tools and processes of decision making processes by the participating 
pharmaceutical firms. The firms could enhance their decision making processes by 
developing a holistic and comprehensive decision-making approach in addition to 
search and selection processes to overcome the challenges of the South African 
pharmaceutical industry and respond to market and industry dynamics. 
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 Types of university specialised knowledge inputs and learning 5.4
 
The interviews in this study revealed that the most frequently mentioned type of 
specialist knowledge input by pharmaceutical firms was scientific knowledge related 
to R&D and technical knowledge in technology development and process 
manufacturing, followed by clinical research knowledge related to access to patients’ 
information and recruitment of patients into clinical research and regulatory 
environment. These findings are not surprising since the South African 
pharmaceutical industry is comprised of firms in the manufacturing area of new or 
drug technologies that are no longer patented or that are not patented. The 
pharmaceutical industry is technology-intensive and requires technological 
knowledge and other inputs (e.g. from universities, biotechnology companies, 
suppliers or even competitors) in order to adapt in ever changing environments 
where markets and technology are unpredictable and changing (Santos 2003). 
Scientific knowledge related to R&D and knowledge in technology development and 
process manufacturing help pharmaceutical firms to solve problems in production or 
manufacturing processes, as well as to make improvements on old or completely 
new technologies as these will increase changes of technology or product 
commercialisation.  
 
These specialised technological knowledge inputs are distributed within the 
boundaries of the R&D, production or manufacturing activities. External technological 
knowledge facilitates the firm learning process in order to be aware of technological 
developments as well as the unmet needs in an environment they are operating in. It 
also allows for securing of protection of intellectual property, mainly through patents, 
to build and sustain competitive advantage relative to their competitors.  
 
The South African pharmaceutical industry is also competitive in conducting clinical 
research due to the population diversity of South Africa, high burden of diseases and 
universities that are connected to hospitals and provide courses in clinical research. 
Pharmaceutical firms involved in clinical research that were interviewed expressed 
the need for knowledge requirement in clinical research from universities. Clinical 
research knowledge requirement by pharmaceutical companies in this case, is the 
102 
 
knowledge relating to how firms can increase effectiveness of clinical research by 
accessing patients’ records and recruiting quality patients into clinical research 
(through universities). The main reasons for pharmaceutical firms requiring this 
specialised knowledge inputs into their clinical research is to better understand how 
new drug product technology works on patients before registration and introduction 
into the market, to fulfill unmet medical needs and drug modalities.  
 
Pharmaceutical firms have also expressed the need to develop their own internal 
expertise in designing protocols for clinical research programmes that would lead to 
enhancing decision-making and assist patient’s safety, and improved identification of 
clinical research sites and investigators. The learning process from clinical research 
knowledge inputs through interaction with the universities take place through 
meetings and training programmes, to assist in building the firm’s relevant internal 
skills and competencies.  
 
The pharmaceutical industry operates within a changing regulatory environment due 
to government policies. The most regulated activities in the pharmaceutical industry 
include clinical research, drug registration, marketing and distribution. But the 
majority of pharmaceutical firms do not have the capacity and expertise on how to 
respond to the ever changing regulatory environment. To address this issue, the 
pharmaceutical firms interviewed noted that knowledge in the regulatory environment 
is important. This is due to the following reasons: to better understand the regulatory 
environment as universities have capacity and experience and offer academic 
courses in this area; achieve submissions on schedule; reduce clinical/non-clinical 
error; increase efficiency in clinical research operations; improve the quality of 
reports based on clinical research; implement improved regulatory timelines, leading 
to reduced MCC questioning; and increased agility to respond to changing regulatory 
requirements  
 
5.4.1 Capturing of specialist knowledge  
 
‘Capture’ is one of the dimensions of innovation management at the firm level, which 
refers to how firms derive value from external specialist knowledge – be it for 
commercial success, market share, cost reduction or social innovation in the 
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changing environment (Tidd and Bessant 2009). There are many ways in which firms 
capture external specialist knowledge. For instance, in this research, it has been 
found that the majority of the pharmaceutical firms operating in South Africa have 
repeatedly mentioned documentation systems as a way of capturing knowledge in 
physical hard copies. This capturing process of external knowledge probably creates 
opportunities for learning and development of innovations within firms which in turn 
would result in building capabilities that the firm desires. The main intention of 
physical hard copies for firms is to learn from completed projects. Abrol, Prajapati 
and Singh (2013) argue that learning in the case of pharmaceutical firms operating in 
developing countries can be in terms of technological lessons learned, for example, 
the acquisition of new processing or product features which add to the organisation’s 
technological competencies. However, Abrol, Prajapati and Singh (2013) point out 
that learning can also be around the capabilities and routines needed for effective 
product innovation management. 
  
Another way in which the pharmaceutical firms that participated in this study capture 
the specialist external knowledge is through knowledge management systems, such 
as electronic programmes and databases. Knowledge management is thought to be 
an effective way for firms to manage knowledge in order to improve performance and 
productivity through innovation (Rašul, Vukšić and Štemberger 2012). It can be 
deduced that pharmaceutical firms in this study capture specialist knowledge through 
these types of knowledge management systems in order to grow the knowledge pool 
of the firm and thus retain critical technical knowledge required for R&D, technology 
and innovation activities. Pharmaceutical firms in the present study are also using 
technology transfer agreements and project management systems as tangible 
assets of technological knowledge for economic gains (Teece 1998). 
 
5.4.2 Codification of the learning process from knowledge inputs 
 
The majority of the pharmaceutical firms codified their learning experiences from the 
universities through electronic document systems, followed by physical hard copies. 
Electronic document systems contain a database of past research papers produced 
by universities. Firms thus search through the database to look for research 
publications of interest. The physical hard copies, on the other hand, may include 
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contracts of previous collaboration with universities; recording and reviewing minutes 
of meetings; score cards; documents and study outcome reports; and business plans 
and strategic plans. Capacity building programmes in the form of mentoring and 
training are also ways by which pharmaceutical firms learn from universities. These 
allow exchange of knowledge and the development of new ideas for new projects. 
Networks are also used by firms with universities to develop learning processes. 
 
It appears that firms belonging to very knowledge-intensive sectors such as the 
pharmaceutical industry, and that produce products whose quality is strictly 
dependent on the ability to acquire knowledge and to accumulate proprietary know-
how learned through its use, tend to rely on external knowledge for new product 
development (Balconi 2002). 
 
 Pharmaceutical firms linkages with universities  5.5
 
5.5.1 Collaboration between firms and universities  
 
According to Rhee and Kim (2010), public research organisations are established 
around the world to become involved in R&D as well as science and technology 
activities, primarily to meet national needs in research and technology areas in which 
firms cannot invest because of high costs and risks. Rhee and Kim (2010) make a 
claim that the role of public research organisations is to occupy a strategic position in 
national innovation systems as central network agents in national knowledge-
generating activities, and to advance the state of knowledge and to disseminate a 
broad spectrum of public information in mostly science and technology areas, 
technologies developed by PROs are transferred to the sector for commercial 
exploitation. Rhee and Kim (2008) further claim that public research organisations 
contribute to building national science and technology by developing new 
technologies, nurturing and training talents, sharing knowledge, and consulting to set 
up technology policies. Around the world, public research organisations function 
within the specific context of a national social, cultural, political, financial and 
economic system, frequently carrying with them the legacies of colonial, post-
colonial and other forms of governance. 
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In South Africa, public research organisations, also known as science councils, were 
established to play a catalytic role in establishing the strong and diverse science, 
engineering and technology to support social and economic development. The 
mandate of science councils in South Africa is to harness research, science and 
technology to support social and economic development through the allocation of 
government money in the form of Parliamentary Grant to carry out their mandate.  
 
This study’s respondents noted that it is often cheaper for the pharmaceutical firms 
to collaborate with universities. For instance, Walwyn (2008) argues that the cost for 
a research project is cheaper in the university sector. The budget allocated for the 
pharmaceutical firms’ knowledge collaboration with universities is not more than two 
and a half million Rands (>R2.5M), suggesting a reason why firms in the 
pharmaceutical industry collaborate with universities. The literature suggests that 
pharmaceutical firms collaborate with universities on R&D to overcome low budget 
for R&D; and to avoid the risky business of performing R&D.  
 
Rhee and Kim (2010) argue that there is often a clash of cultures between public 
research organisations including universities, commercial organisations and firms on 
the approach to research. Rhee and Kim (2010) state that universities place 
emphasis on exploratory or basic research to provide understanding of specific 
aspects of the R&D in order to develop potential technological solutions for industry, 
while government funding agencies simply want implementable solutions that work 
and yield commercial benefits. Firms are strongly focused on commercial research 
that would enable them to return investments to their shareholders on time and 
within budget.  
 
 Summary of the results  5.6
 
According to the literature, the pharmaceutical firms operating in South Africa have 
strong links with public research institutions including universities and use these to 
access specialist knowledge to build their own capabilities for technology 
development and innovation process. This viewpoint was a strong motivation to 
undertake this study in order to provide information on how the pharmaceutical firms 
operating in South Africa make decisions to form linkages with universities on 
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technological knowledge and other inputs. This viewpoint has been unexplored in the 
literature. 
  
Using the research findings obtained in the study, it is argued that the cost model 
factor is not the primary motivator for the pharmaceutical firms participated to form 
linkages with universities. This study therefore contests the notion that firms across 
technology intensive industries such as pharmaceutical firms establish linkages with 
universities because of the partial cost model that universities employ in providing 
research services and thus making it less expensive to provide research services 
compared to science councils (Walwyn 2008).  
 
The study argues that the pharmaceutical firms desire to form linkages with 
universities that conduct quality research, have experienced researchers and 
students to provide production and manufacturing solutions, and have a good track 
record and reputation related to research outputs such as students, publications and 
patents. The study also suggests that these factors are impact on firms’ decision 
making processes through search and selection processes.   
 
The study further makes a profound argument with respect to the international 
pharmaceutical firms operating in South Africa that are involved in clinical research. 
These firms form linkages with universities that are connected to hospital facilities 
where universities have access to patient information and records which are used in 
designing clinical research protocols. In addition, the ability of universities in 
recruiting patients with relevant disease profile to participate in clinical research 
increases firms desirability to form linkages with universities. Furthermore, 
universities with these kinds of characteristics as determined through selection 
process and criteria could assist firms to overcome the regulatory issues imposed by 
the South African government, through the MCC, on these firms wishing to conduct 
clinical research, as universities have a clear understanding of the regulatory 
requirements for clinical research in South Africa. Also, infrastructure linked to the 
research is crucial to firms to enable them to achieve innovation objectives and attain 
competitiveness.  
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In conclusion, this study makes a contribution to the existing literature on university 
and industry linkages on the part of firms operating in the South African 
pharmaceutical industry, by providing an understanding of how they make decisions 
to form linkages with universities on research and technology development. Hence, 
the data from this study states that the decision making process is comprised of 
search, selection and development of selection criteria, as well as evaluation 
processes.   
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6. CHAPTER 6: CONCLUSIONS 
 
 Introduction 6.1
 
This research is a preliminary study into exploring the perspectives of the private 
pharmaceutical firms operating in South Africa which participated in the study 
regarding the management decision making processes for forming linkages with 
universities on research and technology development. This chapter describes 
conclusions related to the research, providing recommendations for senior 
executives and managers of pharmaceutical firms, as well as recommendations for 
further research. 
 
Consequently, the conclusions have been drawn on the types of linkages between 
the pharmaceutical firms which participated in this study and universities, the firms’ 
decision making framework for the formation of linkages with universities and 
preference of these firms to form linkages with the universities. 
 
 Types of linkages between firms and universities  6.2
 
According to Plewa and co-authors, the term “linkages between firm and universities” 
refers to bi-directionality between firms and universities (Plewa et al 2013). Plewa 
and Quester (2007) cited by Plewa et al (2013) argue that linkages between firms 
and universities are created over time, in order to diffuse ideas, skills and people into 
the firms innovation processes. The intention for the establishment of linkages is 
therefore to create mutual value between a firm and a university. There are different 
forms of linkages which have been studied extensively in literature both from the 
perspective of the firm and the university.  
 
This study revealed the types of linkages between the pharmaceutical firms and 
universities, using empirical data. The study found that R&D contracts, sponsored 
R&D, student post graduate research projects, internships, post graduate 
studentships, university consultancy and conferences as types of linkages. The 
predominant types, according to the pharmaceutical firms, are contract research and 
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sponsored R&D.  These were frequently mentioned during elite interviews with the 
senior executives and management of the pharmaceutical firms.  
 
These types of linkages are very much interrelated, meaning that the universities, as 
specialist providers of knowledge, act more as service providers to conduct scientific 
research on behalf of the pharmaceutical firms than a research partner. In this case, 
the pharmaceutical firms pay the research at full cost and as such all the intellectual 
property produced by the universities through scientific research belongs to the 
firms.  
 
The data obtained from the triangulation stage of this research also revealed that 
private pharmaceutical firms are engaging universities through these types of 
linkages.  The university commercial scientific research was revealed as another 
type of linkage, confirming that the private pharmaceutical firms prefer university 
research packaged in a commercial framework. Both findings obtained from elite 
interviews in this study and from the triangulation stage correlate with the findings 
obtained in the Kruss (2012) study.  The latter was based on the South African life 
science industry, which includes the pharmaceutical industry, where it is reported 
that the majority of the private firms are using university collaboration to develop new 
technologies; and to improve R&D expertise and capabilities through linkages.  
 
Furthermore, the findings in this study on the types of linkages corroborate with the 
findings of Siyanbola and co-authors in their study of the type and intensity of 
linkages between firms and universities in the Nigerian pharmaceutical industry 
using a survey of 25 pharmaceutical firms operating in Nigeria (Siyanbola et al 
2012). These authors found that consultancy, staff exchange and fellowship 
programmes and sponsored workshop participants as the most common types of 
linkages. Similar findings were also obtained by Parahons (2009) in the Brazilian 
pharmaceutical industry using a quantitative research methodology in the form of a 
survey.  
 
It can therefore be deduced that firms in the pharmaceutical industry would 
experience similar types of linkages with universities. Hence, it was not surprising to 
the researcher of this study to find out these types of linkages due to the nature of 
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the South African pharmaceutical firms as a knowledge and technology-intensive 
industry.  
 
The pharmaceutical firms, which participated in this study, use linkages with the 
universities as a mechanism to access university knowledge which can be applied in 
technology development and innovation activities. Furthermore, the type of 
knowledge flows linked to linkages that take place between universities and firms in 
the South African pharmaceutical industry, as indicated by the individuals drawn 
from the selected universities and government-owned institutions and national 
departments, are as follows: license agreements; engagement with university 
departments; appointment of experienced researchers; outsourcing clinical research 
expertise; and contract research. Based on these knowledge flows, this study may 
conclude that pharmaceutical firms and universities have formal linkages since they 
involve contractual agreements to access knowledge from universities. This is 
except with engagement with university departments, which take place on an ad hoc 
basis, for instance, a pharmaceutical firm may approach the individual researcher in 
the university department whenever the need arises for scientific knowledge. 
 
  The decision making framework   6.3
 
The qualitative research methodology in the form of elite interviews resulted in the 
emergence of the framework used by the pharmaceutical firms that participated in 
the study when making decisions to link with the universities. The key dimensions of 
the decision-making framework, which influence the type of linkages as well as 
knowledge flows, are as follows: 
  
6.3.1 Search process  
 
Search functions are an important component of the management of innovation at 
the firm level. However, there is insufficient evidence regarding how pharmaceutical 
firms operating in South Africa operationalise this aspect of innovation management 
and how they choose between alternative sources of specialised knowledge. The 
fact that search is important in identifying, processing and selecting information from 
the environment (Tidd and Bessant 2009), gave rise to the following question— How 
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do pharmaceutical firms operating in South Africa perform the process of searching 
for knowledge at universities?  
 
This study collected evidence interviewing executives and senior managers from 
pharmaceutical firms that perform the process of search through patent searches 
using their own patent search engines; consulting or making regular contacts to 
engage universities in meeting settings to find out the kind of research universities 
are doing, and its relevant to their firm, is aligned to the alignment with their 
company’s strategy, cost effectiveness and able to be applied to developing 
technologies that can be commercialised; making regular attendances  of local 
conferences hosted by universities to find out developments in the research 
environment and to create networks and identify potential research partners; 
consulting technology transfer offices located at universities to find out what 
technologies are available; using from their own knowledge management systems 
such as a database of the list of universities and review reports of past collaborations 
with universities; conducting feasibility studies and market analyses to search for any 
signals in the environment.  
 
In addition to these search and scan functions, this study also found that a “word of 
mouth” strategy was also used, probably because of the relatively small size of the 
South African pharmaceutical sector where people know each other. Additionally, 
academic publications are consulted to find out developments with research and 
identify researchers and affiliated institutions; calls for proposals to identify research 
that is aligned to the firm strategy that the firm can fund; and student recruitment to 
attract and employ research with talent.  
 
The majority of the pharmaceutical companies interviewed indicated that they make 
use of people with specialist competences and experiences to undertake the process 
of search and scan functions. This viewpoint was confirmed by the reflections on 
universities’ and government-owned institutions and departments on search process 
by private pharmaceutical firms operating in South Africa. These individuals with 
specialist competencies have been exposed to the research environment either 
through previous post graduate studies and jobs are selected to identify 
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opportunities for innovation and business development such as knowledge, people 
with expertise and market signals.  
 
In the view of the respondents, the search process by the pharmaceutical firms is 
organised as follows: 
 
 Pharmaceutical firms’ consideration to make time to attend local academic 
conferences gives them the opportunity to identify potential researchers 
whose research is aligned to the company’s strategy. This is followed by 
follow-up meetings and further discussions. 
 Most pharmaceutical firms have in-house research programmes to advance 
their innovation, and it becomes easier for firms to engage universities that fit 
their innovation profile and company strategy 
 Pharmaceutical firms have governance structures comprising of scientific 
research board and advisors, who provide advice on research strategy and 
implementation. This capability helps firms to successfully identify universities 
as research partners for the innovation process and develop desired 
technologies with market potential.  
 
Pharmaceutical firms are involved in a search process with the specific intention of 
identifying where to find scientific knowledge and how to apply it in the innovation 
process to improve decision-making effectiveness. This suggests that 
pharmaceutical firms have accumulated internal capabilities with a strong research 
component, and these capabilities enable firms to draw from external knowledge 
sources for innovation. Thus, internal research capabilities together with external 
knowledge play an important role in the innovation process. 
 
This study further explored the factors that shape the search process by 
pharmaceutical firms operating in South Africa for scientific knowledge and other 
inputs at universities. The pharmaceutical firms believe that these factors would play 
a significant role in informing their decisions in identifying the universities in research 
fields which are relevant for their own R&D and innovation activities.  
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The results indicate that among the factors found in this study, the resources 
available at universities for research and clinical research, such as experienced 
researchers in R&D and clinical research, research equipment and research 
laboratories; the reputation of the university in the research frontier for doing and 
producing quality research including commitment to deliver are the most significant 
factors in searching for knowledge from universities. The empirical literature on 
studies of industry-university linkages which focus on the determinants and 
motivation for collaboration in the case of the firms, suggest that reputation and 
quality of university research are responsible for the formation of linkages between 
firms and universities across sectors and contribute to the success of the 
collaboration (Mora-Valentin, Montoro-Sanchez and Guerras-Martin 2004). Other 
factors identified by the present study include university research complementarity to 
the firms and alignment to the company strategy; university research with 
commercial potential and intellectual confidentiality by universities as well as cost 
implications for knowledge acquisition and the public good provided by the 
universities. Strikingly, pharmaceutical firms are not looking for cost-effective 
knowledge acquisition from the universities for their production and manufacturing 
processes. This implies that cost is not a decisive factor on whom to collaborate with.  
The pharmaceutical firms are involved in a search process for external knowledge at 
universities and were able to recognise signals in the marketplace. This implies that 
firms have a degree of knowledge and capabilities related to R&D and technological 
development built over time, which enable them to recognise the knowledge they 
need for innovation.  
 
6.3.2 Selection process 
 
Given the importance of university technological knowledge and other inputs and 
collaboration with firms in the pharmaceutical industry, this research explored factors 
that influence the pharmaceutical firms’ selection process of universities rather than 
other knowledge providers and how such factors influence the firm’s strategic 
decisions. It is interesting to note that the highest scores (both frequency and relative 
frequency) are expertise, experience and scientific knowledge; followed by 
reputation; and relevance and alignment of the university knowledge to firm’s 
business strategy. The individuals drawn from the selected universities and 
114 
 
government-owned institutions and government add to these factors by mentioning 
that the cost model, stage of technology development, historical relations, area of 
research focus and research excellence tied up to quality of research as important 
factors considered by pharmaceutical firms in the selection process for choosing 
universities among other technological knowledge providers.   
 
These results indicate that the factors that the private pharmaceutical firms consider 
are science-based, confirming that the pharmaceutical industry is driven by scientific 
knowledge and dynamic technological development to attain competitiveness. Firms 
which lack the necessary knowledge and abilities will seek to cooperate with 
universities so as to gain access to the know-how and internalise their abilities and 
competence, thereby creating new competencies that are valid for the firm (Bayona, 
Garcia-Marco and Huerta 2001). 
 
Other factors found in this research include research infrastructure; and availability of 
technology transfer offices at universities; and the distance of a university to a firm’s 
location is equally important. These findings can be deduced as important factors 
facilitating the formation of linkages between pharmaceutical firms and universities. 
 
Strikingly, cost implication to acquire university knowledge for technological inputs is 
regarded by pharmaceutical firms as least important in their selection process. This 
is in contrast to the R&D cooperation between firms and universities characterised 
by high transaction costs for knowledge acquisition requiring the presence of 
absorptive capacity and high spillovers to other market actors (Veugelersa and 
Cassiman 2005). These factors influenced the firm’s selection process with a given 
technology or in other words how the firm innovation process affects the firm’s view 
on collaboration with universities.  
 
6.3.3 Characteristics of the universities 
 
Several studies have explored the characteristics of private firms that promote the 
formation of linkages with universities (Arundel and Geuna 2004; Cohen, Nelson and 
Walsh 2002; Fontana et al 2003). University characteristics play a fundamental role 
in firm management decision-making processes and vary from one university to the 
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other and affect the propensity of firms to form linkages with universities (Giuliani 
and Arza 2009). This research found that there are different university characteristics 
that facilitate the pharmaceutical firm’s selection process. The characteristics of the 
universities that pharmaceutical firms operating in South Africa are looking for at 
universities when forming linkages are:  
 
 Trained and experienced personnel and technical expertise 
 International exposure and standing 
 University research relevance to the firm 
 Good track record and reputation 
 Accessibility 
 
These university characteristics may suggest that firms may successfully achieve 
their R&D objectives in projects with universities. This study also found that the 
pharmaceutical firms also look for the following characteristics in universities in order 
to establish linkages: 
 
 research expertise to support firm innovation activities in areas of 
competitive advantage to the firms and building competencies in core 
technological areas 
 historical relationships with the institution based on a track record on 
delivering on research projects on time within time framework agreed upon in 
the contract  
 cost model related to doing the research on behalf of the company. If the 
university has a full cost model, which includes not only the direct project cost 
but includes costs for use of research space and infrastructure, cost of 
salaries and other indirect costs, such as administration and management 
fees for projects, it is unlikely that the firm will choose such a university with a 
full cost model. 
 research focus aligned to the company’s strategy and implementation 
 compliance with drug development standards to receive market approval 
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6.3.4 Selection criteria  
 
The main criteria used by pharmaceutical firms for selecting the universities among 
other knowledge providers is summarised as follows in relative ranking: 
 
 Expertise and experienced researchers  
 Reputation of the university department against international benchmarks 
 Relevance and alignment of the university research to the firm’s strategy 
 Quality of the research in terms of research publications output and research 
excellence tied up to students with necessary talent, and stage of technology 
development in the innovation value chain 
 Research facilities and availability of technology transfer offices within a 
university 
 Cost model 
 
The findings of the study show that the pharmaceutical firms have a diversity of 
technological knowledge providers to choose from, depending on their research, 
technology development and innovation needs.  
 
6.3.5 Evaluation of the decision-making processes  
 
This research indicates that the pharmaceutical firms have few decision- making 
processes and rules. Fewer decision processes probably help pharmaceutical firms 
face the challenge of quickly improving its product technologies and innovation 
activities in the midst of organizational, competitive and marketplace transformation 
including the regulatory environment. 
 
 Interaction of the pharmaceutical firms with universities  6.4
 
The study revealed that the pharmaceutical firms which participated in the study 
show preference to forming linkages with the universities, as 57% of the respondents 
from the participating pharmaceutical firms indicated they collaborated with the 
universities on science and technology projects as opposed to 43% of the 
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respondents who indicated collaborating with the science councils. These findings 
were supported by the views of the individuals and expert commentators drawn from 
universities and national government departments and knowledge producing 
institutions of government.  
 
The respondents noted that it is often cheaper for the pharmaceutical firms to 
collaborate with universities, as Walwyn (2008) argues that the cost for a research 
project is cheaper in the university sector. The literature suggests that 
pharmaceutical firms collaborate with universities on R&D to overcome low budget 
for R&D; and to avoid the risky business of performing R&D.  
 
Kim and Rhee (2010) make a claim that there is often a three-way clash of cultures 
between academic institutions, government funding entities for technological 
innovation and private firms in terms of their approach to R&D. The universities are 
simply interested in providing an understanding of the research phenomenon and 
producing research publications and students which could be used by firms as 
sources of innovation. Companies are interested on research which has a 
commercial potential in order to fulfill their mandate to shareholders – which is 
generating profit on time and within budget.  
 
 Recommendations 6.5
 
This section presents the recommendations based on the research findings, which 
have implications for both firms’ senior executive and senior managers and 
government innovation policy makers.  
 
6.5.1 Firm management 
 
Senior executive and senior managers should investigate a number of issues 
relating to formation of linkages between firms and universities. It is generally 
accepted that firms in high technology-intensive industries such as pharmaceutical 
are using linkages with public research organisations including universities to share 
the resources such as research costs. Only a few of the pharmaceutical firms 
operating in South Africa that participated in this research do not consider a cost 
118 
 
factor in their search and selection processes. It is recommended that senior 
executive and senior managers consider co-funding with public research 
organisations which could be achieved through linkages. They should use co-funding 
to supplement their internal research budget. 
 
Because decision-making is the most critical success factor for firms and improving 
decision-making processes and effectiveness are key to reducing risk and enhancing 
performance to maximise profits. The empirical data of this research highlights that 
pharmaceutical firms go through a series of processes to enhance decision-making 
practices. Some decision-making is done on an ad hoc basis, for example, firms 
would approach universities when the need arises. As such, these processes appear 
not to be organised and effective. The inputs and outputs are, therefore, often not 
defined. It is recommended that senior executive and senior managers implement 
decision-making practices, which may include: 
 
 paying particular attention to the risks of the external collaboration and 
examined financial model for the establishment of linkages with universities, 
sensitivity analysis, and the relationship of those risks to the risks of other 
projects in the firm’s portfolio. Learning from past comparable situations may 
also be beneficial; 
 ensuring that different firm business units such as strategy, marketing and 
finance participate in discussions about any decision and are included on the 
basis of skills and experience; that decision criteria is transparent, and 
decisions are discussed in relation to the organisation’s other strategic 
decisions; and 
 putting the firm’s goals ahead of business unit goals, and encouraging efforts 
to build consensus across business units. 
 
6.5.2 Government innovation policy makers 
 
The basic premise of this research is that the legal, economic, and policy 
environments that comprise the system of innovation determine the rate and type of 
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university knowledge and thereby influence the rate of technological change within 
firms. 
 
Therefore, it is suggested that, in order for the South African Government to be 
successful at promoting linkages between firms and universities, it should be doing 
more to understand innovation processes within private pharmaceutical firms and 
how these firms make decisions to form linkages with universities. The South African 
government should engage firms in the pharmaceutical industry on search and 
selection practices, which could be used to inform decision-making. Furthermore, 
policies are needed that stimulate South African universities to continue engaging 
with firms and to adopt a method of systematic and formal consultation with industry 
in the development of structured Master and PhD programmes that address 
industry’s requirements. 
 
 Suggestion for possible future work 6.6
 
This research is a preliminary study into understanding how firms in the South 
African pharmaceutical industry make decisions to link with public research 
organisations including universities on research and technology development, 
considering search and selection processes. As a preliminary study, it may form part 
of a future longitudinal study that investigates change within the South African 
context.  
 
The future study may include a larger sample of private pharmaceutical firms, in 
order to increase the number of firms in the study. This would aid in better 
understanding the innovation processes and complexities and improving decision-
making effectiveness. Additionally, such a study might help to differentiate between 
private pharmaceutical firms in developed and developing countries, as well as the 
multinational pharmaceutical firms operating in South Africa and local firms, in order 
to better understand the nature of the competition faced by local firms from the 
presence and activities of different international firms. 
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8. APPENDICES 
 Appendix A: Interview protocol directed at the participated pharmaceutical firms 
operating in South Africa 
 
Background  
The purpose of these questions is to explore the perspectives of pharmaceutical firms regarding 
forming collaborations for research and development (R&D), with universities as opposed to science 
councils and other knowledge providers. In particular, I am interested to understand the selection and 
decision-making processes that lead to firms choosing particular university with whom to collaborate. 
 
The questionnaire is directed at R&D Managers, Commercialisation Managers, IP Managers, Senior 
Technology Acquisition Managers, Project Managers and Strategic Collaborations Managers within 
pharmaceutical firms.  
 
The questionnaire has been structured into two separate parts and will take approximately sixty 
minutes. 
 
Thank you 
Sechaba Bareetseng  
Tel.: 012 841 2574contact information   
Cell: 082 332 8367 
Email: sbareetseng@csir.co.za 
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PART 1  
The first part of the interview covers the general profile of respondent firms in terms of company age 
and the broad nature of knowledge collaboration with universities. 
 
 
 
Date: …………………………………………………………………..... 
Company Name: ……………………………………………………… 
Location of the Company: ………………………………………….. 
Interviewee Name: …………………………………………………….  
Interviewee’s Portfolio: ……………………………………………… 
 
What is the nature of your business? 
 
Please select from the following- 
 
Manufacturing 
Export 
Import 
Clinical research 
Quality control 
Packaging 
 
Has your company collaborated with a university? 
 
Yes  
No 
 
If yes, how many R&D collaboration agreements do you have? 
 
What is the nature of your company’s collaboration with universities: 
 
R&D contracts 
Sponsored R&D 
Student postgraduate research projects 
Internships 
Postgraduate Studentships 
University consultancy 
University commercial scientific research  
Conferences 
 
For how many years has your company been collaborating with universities? 
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Does your firm use university collaboration for technological development and innovation? 
Yes  
No  
 
On how many R&D projects have you collaborated with universities? 
To what extent has your company derived value from the collaboration? 
How many patents has your company produced due to collaboration? 
If you have not already done so, does your firm intends to enter into research collaboration with 
universities in the near future? 
Does your firm intend to enter into R&D collaboration with universities? 
Does your firm engage in R&D in-house? 
 
Continuously 
Occasionally 
Never 
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PART 2  
The second part of the interview seeks your perceptions and descriptions of firm activities.   
Searching for universities for collaboration and innovation management 
 
1. How do you scan the environment to keep abreast of research being performed in different 
universities? 
2. Does the process of searching and scanning for knowledge add value to value creation?  If 
yes, why?  
3. Do you use staff with specialist competencies to undertake this search and scan roles and 
functions? 
4. What factors does your company consider when performing a search for knowledge? 
5. How does your firm decide which R&D projects of technologies to explore?  
6. What types of projects are considered by your firm? Do you choose to acquire pure science 
knowledge inputs from universities or do you prefer to have these packaged in a commercial 
framework?   
7. Are you looking for cost-effective manufacturing services from universities?  
8. Where do the decisions on knowledge collaboration get made in your firm? How do these 
decisions get made? Is there an investment committee or other body involved in the approval 
process?  
9. In the case of international firms operating in South Africa, does the approval making process 
involve head office or regional office? Are there thresholds for decisions and approvals that 
are made in South Africa? 
10. Beyond, the approval stage, does the head office or regional office get involved in the 
operational aspect of knowledge collaboration with universities?  
 
 
Selection criteria for choosing among knowledge providers  
 
1. What factors influence your selection of universities rather than other knowledge providers 
and how do these influence your decision? 
2. What characteristics of the universities facilitate your selection? 
3. Has your company collaborated with a science council before?  
 
Yes  
No    
 
4. If yes, what was the experience? 
5. If no, why has your company not collaborated with a science council? 
6. How did your firm manage improving knowledge collaboration over time with universities and 
science councils? 
7. How would you compare the value derived from collaboration with universities as opposed to 
science councils?   
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8. Types of knowledge and learning from the university knowledge  
9. What types of specialised knowledge inputs do you most seek when collaborating? And why? 
10. How do you capture that knowledge? 
11. How do you codify the learning from knowledge inputs and the search process?  
 
Value  
 
1. Why is your firm dedicating resources to knowledge collaboration? 
2. How has university knowledge affected  
3. research activity within your firm; or  
4. innovation activity and/or technological innovation  
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Appendix B: Sample frame of the pharmaceutical firms operating in South Africa from which the sample size of the 
participating pharmaceutical firms emerged which excludes pharmaceutical firms involved in retail and distribution 
Name of a pharmaceutical firm Nature of a business  
 Manufacturing Export Import Clinical 
research 
Quality 
control 
Packaging Regions 
Sub-population 1 
1. Alliance Pharma: Faraday Street X X  X X X GP 
2. Be-Tabs Pharmaceuticals (Pty) Ltd X X X    GP 
3. Divpharm Manufacturing & Packaging – Agvet Site X      GP 
4. Schering-Plough (Pty) Ltd (Site 1) X X X    GP 
5. Aventis Pharma (Pty) Ltd X X X    GP 
6. Mirren (Pty) Ltd X X     GP 
7. Johnson & Johnson Medical (Pty) Ltd X X X    GP 
8. Roche Products (Pty) Ltd X X X    GP 
9. Columbia Pharmaceuticals (Pty) Ltd X X     GP 
10. Hersol Manufacturing Laboratories X X     GP 
11. Isotec Nutrition (Pty) Ltd – Johannesburg X      GP 
12. Pharmaceutical Contractors (Pty) Ltd X      GP 
13. Pharmaceutical Contractors (Pty) Ltd X      GP 
14. Specpharm Holdings (Pty) Ltd X X X    GP 
15. Adcock Ingram Healthcare (Pty) Ltd – Clayville X X X    GP 
16. Adcock Ingram Critical Care (Pty) Ltd X X X    GP 
17. Dismed Criticare (Pty) Ltd X X X    GP 
18. Adcock Ingram Healthcare (Pty) Ltd – Wadeville X      GP 
19. Inspectorate M & L (Pty) Ltd X   X   GP 
20. Alliance Pharma (Pty) Ltd – Wadeville X      GP 
21. Syntacoll (Pty) Ltd X  X    GP 
22. Pharma-Q trading as Cosi Pharmaceuticals X   X   GP 
23. Pharma Natura (Pty) Ltd X X X    GP 
24. MSD (Pty) Ltd X X X X  X GP 
25. Technikon Laboratories (Pty) Ltd – Anvil Road X      GP 
26. Natural Medicinal Services (Tvl) (Pty) Ltd X X     GP 
27. Contractum (Pty) Ltd X X X    GP 
28. Adcock Ingram Limited – Research & Development X      GP 
29. Portfolio Laboratories (Pty) Ltd X      GP 
30. African Oxygen Ltd – Highveld Process Operations 
Plant 
X      GP 
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31. African Oxygen Ltd – Pretoria West Process Operation 
Plant 
X      GP 
32. African Oxygen Ltd – Gases Operation Centre 
(Germiston) 
X X     GP 
33. Air Products SA (Pty) Ltd – Vanderbijlpark X      GP 
34. Air Products S.A. (Pty) Ltd – Kempton Park X      GP 
35. Cyclotope (Pty) Ltd X      GP 
36. Altis Biologics (Pty) Ltd X      GP 
37. Air Liquide (Pty) Ltd – Alrode X      GP 
38. Air Liquide (Pty) – Cape Town X      GP 
39. Dezzo Trading 392 (Pty) Ltd trading as Indo Pharma X X     GP 
40. Sandoz South Africa (Pty) Ltd X X X    GP 
41. SABS TCS    X   GP 
42. Khululekani Laboratories Services CC    X   GP 
43. Analyticon (Pty) Ltd    X   GP 
44. Institute for Pharmaceutical Services    X   GP 
45. Consulting Chemical Laboratories (Pty) Ltd    X   GP 
46. Stainer Laboratories Services (Pty) Ltd    X   GP 
47. Consulting Microbiological Laboratories    X   GP 
48. Sedek Agrikem CC    X   GP 
49. Laboratory & Biological Services    X   GP 
50. Labhouse (Pty) Ltd    X   GP 
51. Bioindustrial Services CC    X   GP 
52. C.V Analytical Consultant (Pty) Ltd    X   GP 
53. Pet Labs Pharmaceuticals (Pty) Ltd   X X  X GP 
54. AstraZeneca Pharmaceuticals (Pty) Ltd   X    GP 
55. Biogaran South Africa (Pty) Ltd  X X    GP 
56. B Braun Medical (Pty) Ltd  X X    GP 
57. Altana Madaus (Pty) Ltd  X X    GP 
58. Abbott Laboratories S.A. (Pty) Ltd  X X X X  GP 
59. Instavet Import & Export (Pty) Ltd  X X    GP 
60. Intervet South Africa (Pty) Ltd  X X    GP 
61. Biotech Laboratories (Pty) Ltd  X X    GP 
62. Novartis South Africa (Pty) Ltd – Spartan  X X    GP 
63. Biovac SA (Pty) Ltd  X X    GP 
64. Boots Healthcare South Africa (Pty) Ltd  X X    GP 
65. Soflens (Pty) Ltd  X X    GP 
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66. GE Healthcare (Pty) Ltd  X X    GP 
67. UCB (SA) (Pty) Ltd  X X    GP 
68. Servier Laboratories South Africa (Pty) Ltd  X X    GP 
69. Ikhambi Health (Pty) Ltd      X GP 
70. Solvay Pharma (Pty) Ltd  X X    GP 
71. Egis Pharmaceuticals South Africa (Pty) Ltd  X X    GP 
72. Pharmacare Limited – Woodmead  X X    GP 
73. Akromed Products (Pty) Ltd  X X    GP 
74. Triomed (Pty) Ltd  X X    GP 
75. Ingelheim Pharmaceuticals (Pty) Ltd – Ferndale  X X    GP 
76. Wyeth South Africa (Pty) Ltd  X X    GP 
77. Xixia Pharmaceuticals (Pty) Ltd  X X    GP 
78. Fresenius Kabi South Africa (Pty) Ltd – JHB  X X    GP 
79. Arrow Pharma S.A. (Pty) Ltd  X X    GP 
80. Eli Lilly (S.A.) (Pty) Ltd  X X    GP 
81. 3M Pharmaceuticals South Africa (Pty) Ltd  X X    GP 
82. H. Lundbeck (Pty) Ltd  X X    GP 
83. Merck (Pty) Ltd  X X    GP 
84. Caps Pharmaceuticals (Pty) Ltd  X X    GP 
85. Allergan Pharmaceuticals (Pty) Ltd  X X    GP 
86. Merck Generics RSA (Pty) Ltd  X X    GP 
87. Donmed Pharmaceuticals (Pty) Ltd  X X    GP 
88. Genop Healthcare (Pty) ltd  X X    GP 
89. Safeline Pharmaceuticals (Pty) Ltd  X X    GP 
90. Bristol-Myers Squibb (Pty)  X X    GP 
91. Teva Pharmaceuticals (Pty) Ltd  X X    GP 
92. Schering (Pty) Ltd  X X    GP 
93. Ferring (Pty) Ltd  X X    GP 
94. Virbac RSA (Pty) Ltd  X X    GP 
95. Ranbaxy (SA) (Pty) Ltd  X X    GP 
96. SCP Pharmaceuticals (Pty) Ltd  X X    GP 
97. Specpharm (Pty) Ltd  X X    GP 
98. Bayer (Pty) Ltd – Isando  X X    GP 
99. Pharmafrica (Pty) Ltd  X X    GP 
100. Pharmachemie (Pty) Ltd  X X    GP 
101. Tyco healthcare (Pty) Ltd  X X    GP 
102. Sanofi-Synthelabo (Pty) Ltd  X X    GP 
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103. Merial South Africa (Pty) Ltd  X X    GP 
104. Sekpharma (Pty) Ltd  X X    GP 
105. Novo Nordisk (Pty) Ltd (Paulshof Site)  X X    GP 
106. Cipla Medpro (Pty) Ltd  X X    GP 
107. Alcon Laboratories (SA) (Pty) Ltd  X X    GP 
108. Omnimed (Pty) Ltd  X X    GP 
109. Key Oncologics (Pty) Ltd  X X    GP 
110. Stiefel Laboratories (SA) (Pty) Ltd  X X    GP 
111. Immuno-Vet Services CC  X X    GP 
112. Innovata Pharmaceuticals  X X    GP 
113. Pharmascript Pharmaceuticals Ltd  X X    GP 
114. Moses Marketing Venture CC  X X    GP 
115. Thusanong Healthcare (Pty) Ltd  X X    GP 
116. Golden Neo-Life Diamite (Pty) Ltd  X X    GP 
117. Tema Medical (Pty) Ltd  X X    GP 
118. Medwich Pharma (Pty) Ltd  X X    GP 
119. Schering-Plough (Pty) Ltd (Site II)  X X    GP 
120. Mediscience (Pty) Ltd  X X    GP 
121. Aurobindo Pharma  X X    GP 
122. CompuPharm (Pty) Ltd   X    GP 
123. Bioforce SA (Pty) Ltd   X    GP 
124. Apex Pharmaceuticals (Pty) Ltd   X    GP 
125. Camox Pharmaceuticals (Pty) Ltd   X    GP 
126. Serono South Africa (Pty) Ltd   X    GP 
127. The Dental Warehouse (Pty) Ltd   X    GP 
128. Medi Challenge (Pty) Ltd   X    GP 
129. Opus Pharmaceuticals (Pty) Ltd   X    GP 
130. MC Pharma (Pty) Ltd   X    GP 
131. Dr Reddy’s Laboratories (Pty) Ltd   X    GP 
132. National Druggist (Pty) Ltd   X    GP 
133. P.V. Berry   X    GP 
134. Medicine Developers International CC   X    GP 
135. Austell Laboratories (Pty) Ltd   X    GP 
136. Pharmaco Distribution (Pty) Ltd   X    GP 
137. Procter & Gamble South Africa (Pty) Ltd   X    GP 
138. Norgine (Pty) Ltd   X    GP 
139. Norbrook Laboratories S.A. (Pty) Ltd   X    GP 
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140. Tshepo Pharmaceuticals (Pty) Ltd   X    GP 
141. Galderma Laboratories S.A. (Pty) Ltd   X    GP 
142. Axim Pharmaceuticals (Pty) Ltd   X    GP 
143. Pharmachem Pharmaceuticals (Pty) Ltd   X    GP 
144. Revision SA (Pty) Ltd   X    GP 
145. Heel South Africa (Pty) Ltd   X    GP 
146. Strides S.A. Pharmaceuticals (Pty) Ltd   X    GP 
147. Biopure South Africa (Pty) Ltd   X    GP 
148. Trinity Pharma (Pty) Ltd   X    GP 
149. Qestmed (Pty) Ltd  X     GP 
150. Reckitt Beckinser Pharmaceuticals (Pty) Ltd  X     GP 
151. African Medicines (Pty) Ltd  X     GP 
152. Equity Pharmaceutical (Pty) Ltd  X     GP 
153. Alclin (Pty) Ltd  X     GP 
Sub-population 2 
154. The Biovac Institute  X    X WC 
155. Anmaraté (Pty) Ltd  X X    WC 
156. Cipla Life Sciences  X X X   WC 
157. Generix International SA (Pty) Ltd  X X    WC 
158. Group Laboratories South Africa (Pty) Ltd  X X    WC 
159. Astellas Pharma (Pty) Ltd  X X    WC 
160. Medpro Pharmaceutica (Pty) Ltd  X X    WC 
161. Pharma Dynamics (Pty)   X X    WC 
162. Orthomedics Pharmaceuticals (Pty) Ltd – CT (M)  X X    WC 
163. Bouwer Bartlett (Pty) Ltd  X X    WC 
164. M. Katovsky CC   X    WC 
165. MeyerZall Laboratories (Pty) Ltd   X    WC 
166. Pfizer Global Manufacturing, A Division Of Pfizer 
Laboratories (Pty) Ltd 
X X X    WC 
167. Pharmaceutical Enterprises (Pty) Ltd X X X    WC 
168. Barrs Pharmaceuticals (Pty) Ltd X X X    WC 
169. Vitalfarm (Pty) Ltd X X X    WC 
170. African Oxygen Ltd – Kuilsriver Process Operation 
Plant 
X      WC 
171. African Oxygen Ltd – George X X     WC 
172. African Oxygen Ltd – Mosselbay X X     WC 
173. iThemba LABS X   X   WC 
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174. Herbal-Homeopathic (Pty) Ltd X X X    WC 
175. GlaxoSmithKline South Africa (Pty) Ltd  X X    WC 
176. Cipla Life Sciences  X X X   WC 
177. Parceval Pharmaceuticals X      WC 
Sub-population 3 
178. Acorn Pharmaceuticals (Pty) Ltd X   X X  KZN 
179. Bayer (Pty) Ltd Animal Health Division – 
Pietermaritzburg 
X X X    KZN 
180. Impilo Drugs (1966) (Pty) Ltd X      KZN 
181. National Bioproducts Institute X X X    KZN 
182. Allied Drug Company (Pty)  X X X    KZN 
183. African Oxygen Ltd – Pietermaritzburg Process 
Operation Plant 
X      KZN 
184. African Oxygen Ltd – Maydon Wharf, Durban X X     KZN 
185. GM Pharmaceuticals (Pty) Ltd X X     KZN 
186. African Oxygen Ltd – NCP CO2 Process Operations 
Plant – Umgeni 
X X     KZN 
187. African Oxygen Ltd – Newcastle X X     KZN 
188. Molecular Diagnostic Services (Pty) Ltd    X   KZN 
189. Pharmacia South Africa (Pty) Ltd  X  X   KZN 
190. Smith & Nephew Pharmaceuticals (Pty) Ltd  X  X   KZN 
191. Hexal Pharma SA (Pty) Ltd  X X    KZN 
192. Resmed Healthcare  X X    KZN 
193. Gulf Drug Company (Pty) Ltd  X X    KZN 
194. Xeragen Laboratories (Pty) Ltd t/a Firstpharm 
Pharmaceuticals 
 X X    KZN 
195. Pfizer Laboratories (Pty) Ltd  X X    KZN 
196. Biochemical & Scientific Consultants CC    X    
Sub-population 4 
197. Bodene (Pty) Limited trading as Intramed X X X    EC 
198. Beta Pharmaceuticals CC  X X    EC 
199. African Oxygen Ltd – Port Elizabeth X      EC 
200. African Oxygen Ltd – East London X X     EC 
201. Zedchem (Pty) Ltd X X     EC 
202. Aspen Pharmacare East London (Pty) Ltd X      EC 
203. Mentholatum-SA   X    EC 
204. Merck Pharmaceuticals Manufacturing (Pty) Ltd X  X    EC 
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205. Pharmedica Laboratories (Pty) Ltd X X     EC 
206. Pharmacare Limited X X X    EC 
207. Divpharm Manufacturing & Packaging – Longdale X X     EC 
208. GR Pharmaceuticals (1967) (Pty) Ltd X X     EC 
209. Ferlot Manufacturing and Packaging (Pty) Ltd X      EC 
Sub-population 5 
210. Centre for Quality Assurance of medicines     X   NW 
211. Research Institute for Industrial Pharmacy    X              NW 
212. Zydus Healthcare (Pty) Ltd   X               NW 
213. Unichem SA (Pty) Ltd   X               NW 
214. LeBasi Pharmaceuticals (Pty) Ltd   X               NW 
Sub-population 6 
215. Micro Healthcare (Pty) Ltd X X X    FS 
216. African Oxygen Ltd – Bloemfontein X X     FS 
217. South African National Control Laboratory for 
Biological Products 
   X   FS 
Sub-population 7 
218. African Oxygen Ltd – Nelspruit X      MP 
Sub-population 8 
219. African Oxygen Ltd – Kimberley X X     NC 
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Appendix D 
 
INTERVIEW PROTOCOL FOR EXPERT COMMENTATORS DRAWN FROM 
UNIVERSITIES 
Background  
 
The purpose of this research is to explore perspectives of private pharmaceutical firms 
operating in South Africa as they form linkages with specialized providers of technological 
knowledge and other inputs, such as universities.    
 
The purpose of these interview questions is to explore the views and opinions of individuals, 
drawn from selected South African universities, regarding knowledge partnerships between 
universities and pharmaceutical companies. Consequently, the aim of the research is to 
investigate how and why pharmaceutical companies select and form linkages with 
universities as opposed to other sources of knowledge inputs, such as science councils. This 
stage of the research is a triangulation process that provides opinions that will be compared 
with those derived from earlier interviews with executives and managers from 
pharmaceutical companies. 
 
The questions are directed at principal or chief researchers, laboratory managers, and senior 
researchers, clinical research investigators at university research departments and 
technology transfer offices at universities.   
 
The interview, using these questions as a guide, should take approximately 30 - 45 minutes. 
 
Thank you 
Sechaba Bareetseng  
Tel.: 012 841 2574 
Cell: 082 332 8367 
Email: sbareetseng@csir.co.za 
These interview questions explore the perspectives of the universities regarding knowledge 
partnerships between universities and pharmaceutical companies in South Africa. 
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Search processes of pharmaceutical companies 
 
 
1. In your opinion, how do pharmaceutical companies operating in South Africa perform the 
knowledge search function? 
 
 How is it organised?  
 Is it effective? 
 What are the typical sources of knowledge? 
 
2. Do you have any sense of why pharmaceutical companies might select universities as 
opposed to other types of research performers such as science councils? 
 
3. In your opinion, how do pharmaceutical companies go about finding out about the research 
that is being performed at universities or which technologies are available at different 
universities? 
 
Selection criteria for choosing among knowledge providers  
 
 
1. In your opinion, what criteria are used by pharmaceutical companies to select universities as 
compared to other knowledge providers, such as science councils?  
 
2. What characteristics of universities facilitate being selected by pharmaceutical companies?  
 
Types of linkages between pharmaceutical companies and knowledge providers 
 
 
1. In your experience, which of these types of linkages do pharmaceutical companies seek from 
universities? For example, do pharmaceutical companies link with universities on- 
R&D contracts 
Sponsored R&D 
Student postgraduate research projects 
Internships 
Postgraduate Studentships 
University consultancy 
University commercial scientific research 
Conferences 
 
2. What types of scientific knowledge outputs are most required by pharmaceutical companies? 
For instance, do pharmaceutical companies prefer knowledge in the form of basic research or 
packaged in commercial framework?   
 
3. What types of knowledge flows take place between universities and pharmaceutical 
companies? 
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4.  How do these knowledge flows influence the firms’ innovation activities? 
 
5. How important is the issue of cost-effective production of knowledge for pharmaceutical 
companies?  How does this affect the likelihood of linkage with universities, as opposed to 
other knowledge production agencies, such as science councils? 
 
Value  
 
1. How has university scientific knowledge contributed to the value of  pharmaceutical 
companies, for instance in terms of: 
 
(i) R&D and technology development activities; or  
(ii) innovation activity  
 
 
N.B: The same interview questions were directed at expert commentators drawn from 
government departments and government knowledge generation institutions. 
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Appendix E: The general profile of the pharmaceutical firms that participated in the present study  
Questions Company 
 1 
Company  
2 
Company 
 3 
Company  
4 
Company  
5 
Company  
6 
Company  
7 
What is the nature of your business Manufacturin
g 
& 
Clinical 
research 
Clinical 
research 
Manufacturing 
& 
packaging 
R&D Manufacturing 
 
 
Clinical 
research 
Clinical 
research 
Has your company collaborated with a 
university? 
Yes Yes Yes Yes Yes Yes Yes 
If yes, how many R&D collaboration 
agreements do you have? 
4 22 1 3 10 65 20 
What is the nature of your company’s 
collaboration with universities 
Internships 
& 
Postgraduate  
Student ships 
Sponsored 
R&D 
Student 
postgraduate 
research 
projects 
& 
University 
consultancy 
R&D 
contracts 
R&D contracts 
& 
Internships 
R&D 
contracts 
R&D 
Contracts 
Sponsored 
R&D & 
University 
consultancy 
For how many years has your company 
been collaborating with universities? 
10 years 15 years 10 years 12 years 10 years 20 years 20 years 
Does your firm use university 
collaboration for technological 
development and innovation? 
Yes No Yes Yes Yes No Yes 
On how many R&D projects have you 
collaborated with universities? 
5 22 4 6 20 40 No answer 
To what extent has your company derived 
value from the collaboration? 
High High Varies High High High High 
How many patents has your company 
produced due to collaboration? 
1 None 0 1 5 0 0 
If you have not already done so, does 
your firm intends to enter into research 
collaboration with universities in the near 
future? 
Yes Yes Yes Yes Yes Yes Yes 
Does your firm intend to enter into R&D 
collaboration with universities? 
Yes Yes Yes Yes Yes Yes Yes 
Does your firm engage in R&D in-house? Continuously Occasionally Continuously Continuously Occasionally Never Continuously 
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Questions Company 
 8 
Company  
9 
Company 
 10 
Company  
11 (a) 
Company  
12 (b) 
Company  
13 
Company  
14 
What is the nature of your business Export 
Clinical 
research 
Quality control 
Manufacturing Clinical Research Manufacturing Manufacturing 
Export 
Import 
Import 
Clinical 
Research 
Quality Control 
Manufacturing 
Export 
(R&D) 
Has your company collaborated with a 
university? 
Yes Yes Yes Yes Yes Yes Yes 
If yes, how many R&D collaboration 
agreements do you have? 
40 0 5 1 None 15 3 
What is the nature of your company’s 
collaboration with universities 
R&D contracts 
Sponsored 
R&D 
Conferences 
Postgraduate 
Studentships 
University 
consultancy 
R&D contracts 
Sponsored R&D 
R&D contracts, 
Internships, 
Postgraduate 
studentships, 
University 
consultancy 
University 
consultancy 
Sponsored 
R&D 
R&D contracts 
Internships 
 
For how many years has your company been 
collaborating with universities? 
 
75 years 
 
30 years 
 
12 years 
 
40 years 
 
5 years 
 
20 years 
 
12 years 
Does your firm use university collaboration for 
technological development and innovation? 
Yes No No No No No Yes 
On how many R&D projects have you 
collaborated with universities? 
>100 Not sure 7 >10 None 30 Many 
To what extent has your company derived 
value from the collaboration? 
Crucial – helps 
with patient 
recruitment 
Mainly 
intellectual 
value through 
collaboration 
Gained expertise 
in the design of 
clinical trial 
protocols; access 
to patient 
population 
Enable to bring 
new products to 
market; 
enhance skill 
base 
 
Solving of 
production 
process 
through 
technical 
expertise 
 
Success on 
clinical 
research; ability 
to deliver on 
patients for 
clinical 
research 
Gained 
expertise and 
knowledge on 
registration to 
conduct clinical 
trials 
How many patents has your company 
produced due to collaboration? 
0 0 0 0 0 0 0 
If you have not already done so, does your 
firm intends to enter into research 
collaboration with universities in the near 
future? 
Yes No Yes Yes No No Yes 
Does your firm intend to enter into R&D 
collaboration with universities? 
Yes No Yes Yes Yes No Yes 
Does your firm engage in R&D in-house? Continuously Continuously Continuously Occasionally Never Continuously Continuously 
Please note: 11 (a) and 12 (b) represent the same pharmaceutical firms 
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Questions Company 
 15 
Company  
16 
Company 
 17 
Company  
18 
Company  
19 
Company  
20 
What is the nature of your business Manufacturing Export Manufacturing 
Clinical research 
Manufacturing 
Export 
Import 
Quality control 
Packaging 
Manufacturing 
Import 
Clinical 
research 
Import 
Distribution 
Research 
Has your company collaborated with a university? Yes Yes Yes Yes No Yes 
If yes, how many R&D collaboration agreements do you 
have? 
No response 0 Many 1 No response 2 
What is the nature of your company’s collaboration with 
universities 
Conferences Postgraduat
e 
studentships 
R&D contracts 
Sponsored R&D 
Student 
postgraduate 
research projects, 
Postgraduate 
Studentships, 
University 
commercial 
scientific 
research, 
Conferences 
No Sponsored R&D, 
University 
commercial 
scientific research 
(Business support) 
For how many years has your company been collaborating 
with universities? 
7 years 30 years 17 years 5 years N/A 5 
Does your firm use university collaboration for 
technological development and innovation? 
Yes Yes Yes Yes No Yes 
On how many R&D projects have you collaborated with 
universities? 
N/A Many 25 projects 1 No 5 
To what extent has your company derived value from the 
collaboration? 
N/A Immense 
and 
immeasurabl
e value 
Helped to 
register drugs in 
South Africa 
Were able to 
commercialise 
their research and 
filed patents 
No response No really 
How many patents has your company produced due to 
collaboration? 
N/A 0 0 15 0 0 
If you have not already done so, does your firm intends to 
enter into research collaboration with universities in the 
near future? 
 
No response 
 
N/A 
 
N/A 
 
Yes 
 
Yes 
 
Unlikely 
Does your firm intend to enter into R&D collaboration with 
universities? 
N/A Yes N/A Yes Yes No 
Does your firm engage in R&D in-house? Never Occasionally Continuously Never Continuously Occasionally 
 
 
